|
humans |
69 |
|
male |
61 |
|
hepatocellular carcinoma |
59 |
|
adult |
54 |
|
female |
52 |
|
middle aged |
49 |
|
aged |
44 |
|
liver transplantation |
43 |
|
medical sciences |
38 |
|
prognosis |
31 |
|
adolescent |
29 |
|
survival analysis |
29 |
|
treatment outcome |
29 |
|
animals |
28 |
|
retrospective studies |
27 |
|
time factors |
27 |
|
cell line, tumor |
24 |
|
living donors |
24 |
|
reverse transcriptase polymerase chain reaction |
24 |
|
surgery |
24 |
|
follow-up studies |
23 |
|
hong kong - epidemiology |
23 |
|
up-regulation |
23 |
|
gastroenterology medical sciences |
22 |
|
hepatectomy |
22 |
|
immunohistochemistry |
21 |
|
aged, 80 and over |
20 |
|
hcc |
20 |
|
mice |
20 |
|
age factors |
19 |
|
cirrhosis |
19 |
|
immunosuppressive agents - therapeutic use |
19 |
|
postoperative complications |
19 |
|
recurrence |
19 |
|
hepatectomy - methods |
18 |
|
liver cirrhosis |
18 |
|
liver transplantation - methods |
18 |
|
mice, nude |
18 |
|
survival |
18 |
|
survival rate |
18 |
|
transfection |
18 |
|
cadaver |
17 |
|
cohort studies |
17 |
|
disease-free survival |
17 |
|
graft survival |
17 |
|
liver transplantation - adverse effects |
17 |
|
antiviral agents - therapeutic use |
16 |
|
apoptosis |
16 |
|
carcinoma, hepatocellular - metabolism - pathology |
16 |
|
disease progression |
16 |
|
elderly |
16 |
|
gene expression profiling |
16 |
|
liver neoplasms - metabolism - pathology |
16 |
|
rna, messenger - metabolism |
16 |
|
β-catenin |
16 |
|
angiogenesis |
15 |
|
child, preschool |
15 |
|
hong kong |
15 |
|
multivariate analysis |
15 |
|
prospective studies |
15 |
|
rats |
15 |
|
transarterial chemoembolization |
15 |
|
advanced hepatocellular carcinoma |
14 |
|
blotting, western |
14 |
|
cell proliferation |
14 |
|
enzyme-linked immunosorbent assay |
14 |
|
liver cancer |
14 |
|
mortality |
14 |
|
mutation |
14 |
|
peptidyl-prolyl-isomerase |
14 |
|
pin1 |
14 |
|
advanced hcc |
13 |
|
carcinoma, hepatocellular - mortality - pathology - surgery |
13 |
|
child |
13 |
|
child-pugh a |
13 |
|
dose-response relationship, drug |
13 |
|
gastroenterology |
13 |
|
incidence |
13 |
|
infant |
13 |
|
liver function tests |
13 |
|
liver neoplasms - pathology - surgery |
13 |
|
liver transplantation - immunology |
13 |
|
living donor liver transplant |
13 |
|
neoplasm invasiveness |
13 |
|
neoplasm metastasis |
13 |
|
neoplasm recurrence, local - surgery |
13 |
|
reoperation |
13 |
|
sorafenib |
13 |
|
tissue donors |
13 |
|
ablation |
12 |
|
acute disease |
12 |
|
blood transfusion |
12 |
|
carcinoma, hepatocellular - mortality - surgery |
12 |
|
chemicals and cas registry numbers |
12 |
|
cytology and histology |
12 |
|
drug therapy, combination |
12 |
|
emergencies |
12 |
|
hepatitis b - complications |
12 |
|
liver - metabolism |
12 |
|
liver diseases - surgery |
12 |
|
liver neoplasms - mortality - pathology - surgery |
12 |
|
liver neoplasms - mortality - surgery |
12 |
|
organ size |
12 |
|
pediatric liver transplantation |
12 |
|
postoperative complications - epidemiology |
12 |
|
radiofrequency ablation |
12 |
|
tomography, x-ray computed |
12 |
|
beta catenin |
11 |
|
biliary atresia |
11 |
|
carcinoma, hepatocellular - etiology - genetics - metabolism |
11 |
|
carcinoma, hepatocellular - genetics |
11 |
|
carcinoma, hepatocellular - genetics - metabolism - pathology - virology |
11 |
|
carcinoma, hepatocellular - mortality - therapy |
11 |
|
catheter ablation |
11 |
|
cell line |
11 |
|
cyclin d1 - biosynthesis - genetics |
11 |
|
cytoskeletal proteins - genetics |
11 |
|
down-regulation |
11 |
|
hepatitis |
11 |
|
hepatitis b virus |
11 |
|
hepatitis b virus - genetics |
11 |
|
high-intensity focused ultrasound |
11 |
|
intraoperative complications - epidemiology |
11 |
|
lamivudine - therapeutic use |
11 |
|
laparoscopy |
11 |
|
liver |
11 |
|
liver neoplasms - genetics |
11 |
|
liver neoplasms - genetics - metabolism - pathology - virology |
11 |
|
liver neoplasms - mortality - therapy |
11 |
|
liver resection |
11 |
|
liver transplant |
11 |
|
liver transplantation - statistics & numerical data |
11 |
|
metastasis |
11 |
|
neoplasm staging |
11 |
|
oncology medical sciences |
11 |
|
peptidylprolyl isomerase - biosynthesis - genetics |
11 |
|
radiology and nuclear medicine pharmacy and pharmacology biology |
11 |
|
rats, sprague-dawley |
11 |
|
reverse transcriptase inhibitors - therapeutic use |
11 |
|
risk factors |
11 |
|
rna, messenger - genetics - metabolism |
11 |
|
trans-activators - genetics |
11 |
|
transplantation, heterologous |
11 |
|
tumor cells, cultured |
11 |
|
allergology and immunology |
10 |
|
blood loss, surgical |
10 |
|
bridging therapy |
10 |
|
carcinoma |
10 |
|
carcinoma, hepatocellular - surgery |
10 |
|
china |
10 |
|
cyclosporine - therapeutic use |
10 |
|
dna primers |
10 |
|
hepatitis b, chronic - complications |
10 |
|
hospital mortality |
10 |
|
lamivudine |
10 |
|
length of stay |
10 |
|
liver neoplasms - surgery |
10 |
|
liver transplantation - methods - statistics and numerical data |
10 |
|
living donors - supply and distribution |
10 |
|
morbidity |
10 |
|
new technology |
10 |
|
preoperative care |
10 |
|
proteomics |
10 |
|
scarce deceased donors |
10 |
|
signal transduction |
10 |
|
structure-activity relationship |
10 |
|
surgery medical sciences |
10 |
|
tissue donors - supply and distribution |
10 |
|
vascular surgical procedures - methods |
10 |
|
venous infiltration |
10 |
|
11c-acetate |
9 |
|
base sequence |
9 |
|
bile ducts - surgery |
9 |
|
body weight |
9 |
|
cancer invasion |
9 |
|
cancer survival |
9 |
|
carcinoma, hepatocellular - pathology - surgery |
9 |
|
carrier state |
9 |
|
contrast ct |
9 |
|
dna, viral - analysis |
9 |
|
down-regulation - drug effects |
9 |
|
electrophoresis, gel, two-dimensional |
9 |
|
endocrinology |
9 |
|
fatal outcome |
9 |
|
gene expression |
9 |
|
gene expression regulation, neoplastic |
9 |
|
genes, p53 |
9 |
|
hepatocellular |
9 |
|
hifu |
9 |
|
hospitals, university |
9 |
|
hsp70 heat-shock proteins - metabolism |
9 |
|
inflammation |
9 |
|
invasiveness |
9 |
|
laparoscopic liver resection |
9 |
|
liver - pathology |
9 |
|
liver circulation - physiology |
9 |
|
liver diseases - epidemiology |
9 |
|
liver failure - surgery |
9 |
|
liver neoplasms - genetics - metabolism - pathology |
9 |
|
liver transplantation - mortality |
9 |
|
living donor |
9 |
|
microsatellite repeats |
9 |
|
milan criteria |
9 |
|
non-invasive treatment |
9 |
|
oligonucleotide array sequence analysis |
9 |
|
palliative care |
9 |
|
pet/ct |
9 |
|
postoperative complications - classification - epidemiology |
9 |
|
predictive value of tests |
9 |
|
rats, inbred lew |
9 |
|
referral and consultation |
9 |
|
rna, neoplasm - genetics |
9 |
|
severity of illness index |
9 |
|
spectrometry, mass, matrix-assisted laser desorption-ionization |
9 |
|
sphingosine - analogs & derivatives |
9 |
|
transcription factors - metabolism |
9 |
|
acetic acid c 11 |
8 |
|
advanced cancer |
8 |
|
adverse events |
8 |
|
alanine transaminase - blood |
8 |
|
biliary atresia - complications - surgery |
8 |
|
bilirubin - blood |
8 |
|
cadaver donor |
8 |
|
cancer cell culture |
8 |
|
cancer recurrence |
8 |
|
carcinoma, hepatocellular - complications/diagnosis - surgery |
8 |
|
carcinoma, hepatocellular - enzymology - genetics |
8 |
|
carcinoma, hepatocellular - enzymology - pathology |
8 |
|
carcinoma, hepatocellular - genetics - metabolism - pathology - secondary |
8 |
|
catheter ablation - methods |
8 |
|
cell cycle |
8 |
|
cell division - physiology |
8 |
|
cell movement |
8 |
|
cell proliferation - drug effects |
8 |
|
cell transformation, neoplastic - genetics - metabolism |
8 |
|
chemoembolization, therapeutic - adverse effects - mortality |
8 |
|
child-pugh b |
8 |
|
cholangiocarcinoma |
8 |
|
chronic disease |
8 |
|
cisplatin |
8 |
|
combined modality therapy |
8 |
|
complications of liver transplantation |
8 |
|
cyclin-dependent kinase inhibitor p16 - genetics - metabolism |
8 |
|
deceased donor liver transplantation |
8 |
|
disease severity |
8 |
|
elasticity imaging techniques - methods |
8 |
|
fluorodeoxyglucose f 18 |
8 |
|
focal adhesion kinase 2 - metabolism |
8 |
|
gene expression regulation |
8 |
|
gene expression regulation, neoplastic - genetics |
8 |
|
general surgery |
8 |
|
gist |
8 |
|
heme oxygenase-1 |
8 |
|
hepatectomy - adverse effects |
8 |
|
hepatectomy - methods - mortality |
8 |
|
hepatic encephalopathy - surgery |
8 |
|
hepatitis b antibodies |
8 |
|
hepatitis b, chronic - pathology |
8 |
|
infusions, intra-arterial |
8 |
|
inhibitor of differentiation protein 1 |
8 |
|
ischemia-reperfusion injury |
8 |
|
liver cell carcinoma |
8 |
|
liver cirrhosis - complications |
8 |
|
liver cirrhosis - pathology - virology |
8 |
|
liver diseases - etiology - surgery |
8 |
|
liver failure - etiology - surgery |
8 |
|
liver failure - pathology - virology |
8 |
|
liver metastasis |
8 |
|
liver neoplasms - blood - surgery |
8 |
|
liver neoplasms - complications/diagnosis - surgery |
8 |
|
liver neoplasms - enzymology - genetics |
8 |
|
liver neoplasms - enzymology - pathology |
8 |
|
liver transplantation - adverse effects - statistics & numerical data |
8 |
|
liver transplantation - contraindications - methods - mortality - statistics & numerical data |
8 |
|
liver transplantation - methods - mortality |
8 |
|
living-related liver transplantation |
8 |
|
marginal graft |
8 |
|
medicine & public health |
8 |
|
microcirculation |
8 |
|
microscopy, electron |
8 |
|
neoplastic cells, circulating - pathology |
8 |
|
neovascularization, pathologic - metabolism |
8 |
|
nitric oxide synthase type ii |
8 |
|
organ size - physiology |
8 |
|
pancreaticoduodenectomy |
8 |
|
pediatric liver transplant |
8 |
|
polymerase chain reaction |
8 |
|
portoenterostomy, hepatic |
8 |
|
postoperative care |
8 |
|
postoperative complications - prevention & control |
8 |
|
proportional hazards models |
8 |
|
propylene glycols - pharmacology |
8 |
|
reduced-size liver transplant |
8 |
|
reduced-size liver transplantation |
8 |
|
repressor proteins |
8 |
|
resection |
8 |
|
retinoblastoma protein - genetics - metabolism |
8 |
|
sensitivity and specificity |
8 |
|
thrombosis - diagnosis - etiology - surgery |
8 |
|
tissue donors - statistics & numerical data |
8 |
|
tki |
8 |
|
transcription factors - genetics - metabolism - physiology |
8 |
|
transplantation |
8 |
|
transplantation, homologous |
8 |
|
tumor suppressor protein p53 - metabolism |
8 |
|
tyrosine-kinase inhibitor |
8 |
|
vascular endothelial growth factor a - metabolism |
8 |
|
waiting list |
8 |
|
abdominal surgery |
7 |
|
activities of daily living |
7 |
|
acute-on-chronic liver failure |
7 |
|
adenine - analogs & derivatives - therapeutic use |
7 |
|
adiponectin |
7 |
|
adiponectin - blood - chemistry - genetics |
7 |
|
adiponectin oligomeric form |
7 |
|
adjuvant therapy |
7 |
|
american society of anaesthesiologists (asa) |
7 |
|
amino acid sequence |
7 |
|
anastomosis, roux-en-y |
7 |
|
anastomosis, surgical |
7 |
|
anastomosis, surgical - methods |
7 |
|
anti-angiogenesis |
7 |
|
anti-steatosis |
7 |
|
apoptosis - drug effects |
7 |
|
arginase |
7 |
|
arginine |
7 |
|
aspartate aminotransferases - blood |
7 |
|
beta catenin - genetics |
7 |
|
bile duct diseases - etiology |
7 |
|
bile ducts - blood supply - surgery |
7 |
|
bone marrow transplantation |
7 |
|
cadaveric transplantation |
7 |
|
cadherins - metabolism |
7 |
|
carcinoma, hepatocellular - blood supply - drug therapy - pathology |
7 |
|
carcinoma, hepatocellular - diagnosis - pathology - surgery |
7 |
|
carcinoma, hepatocellular - drug therapy - physiopathology - secondary |
7 |
|
carcinoma, hepatocellular - metabolism - pathology - secondary |
7 |
|
carcinoma, hepatocellular - mortality - pathology - therapy |
7 |
|
carcinoma, hepatocellular - therapy |
7 |
|
cardiac surgery |
7 |
|
catheters, indwelling |
7 |
|
cell differentiation |
7 |
|
cell survival signaling |
7 |
|
cell transformation, neoplastic - metabolism |
7 |
|
chemokine cxcl10 - metabolism |
7 |
|
children |
7 |
|
chinese |
7 |
|
cholecystitis, acute - surgery |
7 |
|
cholecystostomy - instrumentation - methods |
7 |
|
cholestasis - etiology |
7 |
|
chronic hepatitis b |
7 |
|
colorectal cancer |
7 |
|
combined resection |
7 |
|
complication |
7 |
|
cyclin d1 - genetics |
7 |
|
cyclin-dependent kinase inhibitor p21 |
7 |
|
cyclooxygenase-2 |
7 |
|
disease models, animal |
7 |
|
dna-binding proteins - metabolism |
7 |
|
domino liver transplant |
7 |
|
drug resistance, viral - genetics |
7 |
|
endothelial cells - drug effects |
7 |
|
endothelin-1 - genetics |
7 |
|
epithelial cells - metabolism - physiology |
7 |
|
experience |
7 |
|
fatty liver - pathology - surgery |
7 |
|
genes, p53 - genetics |
7 |
|
glycogen synthase kinase 3 - metabolism |
7 |
|
graft rejection |
7 |
|
graft rejection - blood - drug therapy - pathology |
7 |
|
graft survival - drug effects |
7 |
|
head of pancreas |
7 |
|
hepatic artery - surgery |
7 |
|
hepatic microcirculation |
7 |
|
hepatic stellate cells |
7 |
|
hepatitis - surgery |
7 |
|
hepatitis b - drug therapy - prevention & control - surgery |
7 |
|
hepatitis b e antigens - blood |
7 |
|
hepatitis b surface antigens - analysis |
7 |
|
hepatitis b, chronic - complications - drug therapy - pathology |
7 |
|
hepatocytes - cytology |
7 |
|
high-intensity focused ultrasound ablation - methods |
7 |
|
histocompatibility |
7 |
|
hong kong chinese |
7 |
|
hypoxia-inducible factor 1, alpha subunit - metabolism |
7 |
|
immunosuppressive agents - pharmacology |
7 |
|
indocyanine green clearance |
7 |
|
informed consent |
7 |
|
inhibitor of differentiation protein 1 - antagonists & inhibitors - genetics - metabolism |
7 |
|
intercellular signaling peptides and proteins - metabolism |
7 |
|
limon |
7 |
|
liver - metabolism - pathology |
7 |
|
liver cirrhosis - blood - metabolism - pathology - virology |
7 |
|
liver diseases - congenital - mortality - surgery |
7 |
|
liver diseases - epidemiology - surgery |
7 |
|
liver neoplasms |
7 |
|
liver neoplasms - complications - surgery |
7 |
|
liver neoplasms - diagnosis - pathology - surgery |
7 |
|
liver neoplasms - drug therapy - physiopathology - secondary |
7 |
|
liver neoplasms - mortality - pathology - therapy |
7 |
|
liver neoplasms, experimental - blood supply - drug therapy - pathology |
7 |
|
liver transplantation - adverse effects - methods |
7 |
|
liver transplantation - adverse effects - methods - mortality |
7 |
|
liver transplantation - adverse effects - methods - pathology - statistics & numerical data |
7 |
|
liver transplantation - methods - physiology |
7 |
|
living donor liver transplantation |
7 |
|
living donors - classification |
7 |
|
logistic models |
7 |
|
long-term outcome |
7 |
|
macrophage |
7 |
|
matrix metalloproteinase 9 - metabolism |
7 |
|
microarray analysis - methods |
7 |
|
microsurgery |
7 |
|
microvascular anastomosis |
7 |
|
model for end-stage liver disease |
7 |
|
molecular weight |
7 |
|
neoplasm invasiveness - genetics |
7 |
|
neoplasm proteins - genetics |
7 |
|
neovascularization, pathologic - drug therapy |
7 |
|
nitric oxide synthase - metabolism |
7 |
|
nuclear proteins - metabolism |
7 |
|
oligodeoxyribonucleotides, antisense - pharmacology - therapeutic use |
7 |
|
olt |
7 |
|
overall survival |
7 |
|
p53 |
7 |
|
patient selection |
7 |
|
peg-rharg1 |
7 |
|
pegylated interferon alfa-2a |
7 |
|
peptidylprolyl isomerase - genetics |
7 |
|
percutaneous transhepatic cholecystostomy (ptc) |
7 |
|
phosphonic acids |
7 |
|
phosphorylation |
7 |
|
portal vein |
7 |
|
portal vein resection |
7 |
|
post-transplantation lymphoproliferative disease |
7 |
|
postoperative complications - prevention & control - surgery |
7 |
|
proliferating cell nuclear antigen |
7 |
|
proliferating cell nuclear antigen - analysis |
7 |
|
proline-rich tyrosine kinase2 (pyk2) |
7 |
|
propylene glycols - therapeutic use |
7 |
|
proto-oncogene proteins c-akt |
7 |
|
pulse spectrophotometry |
7 |
|
recurrent hcc |
7 |
|
registries |
7 |
|
right-lobe |
7 |
|
rna interference |
7 |
|
salvage therapy |
7 |
|
sepsis - prevention & control |
7 |
|
serum albumin - analysis |
7 |
|
solid organ transplantation |
7 |
|
split graft liver transplant |
7 |
|
stat5 transcription factor - biosynthesis - genetics - metabolism |
7 |
|
statistics as topic |
7 |
|
stents |
7 |
|
sustained virological response |
7 |
|
thalidomide |
7 |
|
thoracic surgery |
7 |
|
thrombosis - prevention & control |
7 |
|
tissue array analysis |
7 |
|
transcriptional activation - physiology |
7 |
|
transfection - methods |
7 |
|
transplantation, isogeneic |
7 |
|
transthyretin |
7 |
|
tumor markers, biological - metabolism |
7 |
|
tumor suppressor proteins - metabolism |
7 |
|
twist transcription factor - metabolism |
7 |
|
up-regulation - genetics |
7 |
|
usg-guided |
7 |
|
val30ala |
7 |
|
vascular endothelial growth factor a - blood |
7 |
|
vascular endothelial growth factor a - genetics - metabolism - secretion |
7 |
|
vascular surgery |
7 |
|
whipple operation |
7 |
|
xenograft model antitumor assays |
7 |
|
acute kidney injury - surgery |
6 |
|
adrenal cortex hormones - administration & dosage |
6 |
|
advanced pancreatic cancer |
6 |
|
akt |
6 |
|
akt signaling pathway |
6 |
|
alpps |
6 |
|
amino acid motifs |
6 |
|
amino acid substitution |
6 |
|
analysis of variance |
6 |
|
angiopoietin-like 4 |
6 |
|
antibodies, monoclonal - administration & dosage - therapeutic use |
6 |
|
antigens, cd34 - metabolism |
6 |
|
antigens, viral - blood |
6 |
|
antineoplastic agents - adverse effects - therapeutic use |
6 |
|
antineoplastic agents - pharmacology |
6 |
|
antineoplastic agents - therapeutic use |
6 |
|
antineoplastic agents, hormonal - administration & dosage |
6 |
|
antiviral therapy |
6 |
|
asia |
6 |
|
asian |
6 |
|
azathioprine - therapeutic use |
6 |
|
bcl-x protein - genetics - metabolism |
6 |
|
bevacizumab |
6 |
|
biliary anastomotic stricture |
6 |
|
biliary stricture |
6 |
|
biliary tract diseases |
6 |
|
biological therapy |
6 |
|
blood loss, surgical - prevention & control |
6 |
|
cancer staging |
6 |
|
carcinoma, hepatocellular - complications - surgery |
6 |
|
carcinoma, hepatocellular - diagnosis - therapy |
6 |
|
carcinoma, hepatocellular - drug therapy - metabolism - secondary |
6 |
|
carcinoma, hepatocellular - drug therapy - mortality |
6 |
|
carcinoma, hepatocellular - drug therapy - pathology - surgery - virology |
6 |
|
carcinoma, hepatocellular - epidemiology - surgery |
6 |
|
carcinoma, hepatocellular - etiology - pathology - surgery - virology |
6 |
|
carcinoma, hepatocellular - genetics - metabolism - pathology |
6 |
|
carcinoma, hepatocellular - genetics - mortality - pathology - surgery - therapy |
6 |
|
carcinoma, hepatocellular - genetics - prevention and control - secondary |
6 |
|
cdna microarray |
6 |
|
cell cycle - genetics |
6 |
|
cell cycle proteins - genetics |
6 |
|
cell cycle proteins - metabolism |
6 |
|
chemocytotoxic |
6 |
|
chemoembolization, therapeutic |
6 |
|
chemokines |
6 |
|
complex liver resection |
6 |
|
controlled study |
6 |
|
cyclin d1 - metabolism |
6 |
|
cyclin-dependent kinase inhibitor p27 |
6 |
|
cytomegalovirus - immunology |
6 |
|
cytoplasm - metabolism |
6 |
|
diabetes mellitus - epidemiology - prevention & control |
6 |
|
diagnostic imaging |
6 |
|
dna - analysis |
6 |
|
dna mutational analysis |
6 |
|
dna, viral - blood |
6 |
|
donor hepatectomy |
6 |
|
duct-to-duct anastomosis |
6 |
|
endoscopic treatment |
6 |
|
endothelin-1 - genetics - metabolism |
6 |
|
endothelium, vascular - pathology |
6 |
|
enzyme inhibitors - pharmacology |
6 |
|
epithelial-mesenchymal transition |
6 |
|
erc |
6 |
|
erlotinib |
6 |
|
extracellular signal-regulated map kinases - metabolism |
6 |
|
family history |
6 |
|
focal adhesion kinase |
6 |
|
fty720 |
6 |
|
g1 phase - drug effects |
6 |
|
gemcitabine |
6 |
|
gene expression regulation - physiology |
6 |
|
gold(iii) compound |
6 |
|
gpx3 |
6 |
|
graft |
6 |
|
graft rejection - epidemiology - prevention & control |
6 |
|
growth arrest and dna damage (gadd) inducible genes |
6 |
|
heme oxygenase (decyclizing) - genetics |
6 |
|
hepatic veins - surgery |
6 |
|
hepaticojejunostomy |
6 |
|
hepatitis b - complications - genetics - metabolism - pathology - virology |
6 |
|
hepatitis b - prevention & control - surgery |
6 |
|
hepatitis b surface antigens - analysis - blood |
6 |
|
hepatitis b virus - isolation and purification |
6 |
|
hepatitis b, chronic - mortality - surgery |
6 |
|
hepatocellular carcinoma (hcc) |
6 |
|
hipsc-mscs |
6 |
|
homeodomain proteins - antagonists and inhibitors - genetics - metabolism |
6 |
|
homeodomain proteins - genetics - metabolism |
6 |
|
homeoprotein six1 |
6 |
|
hypertension, portal - etiology - physiopathology |
6 |
|
immunoglobulins - therapeutic use |
6 |
|
immunosuppressive agents - administration & dosage - therapeutic use |
6 |
|
inflow |
6 |
|
injections, intravenous |
6 |
|
interference |
6 |
|
interferon-alpha - adverse effects - therapeutic use |
6 |
|
kidney neoplasms - genetics - prevention and control - secondary |
6 |
|
laparoscopic resection |
6 |
|
ldlt |
6 |
|
ligation |
6 |
|
lipocalins |
6 |
|
liver - anatomy & histology |
6 |
|
liver - blood supply - metabolism - pathology - surgery |
6 |
|
liver - blood supply - pathology |
6 |
|
liver - cytology - metabolism - pathology |
6 |
|
liver - pathology - ultrasonography |
6 |
|
liver neoplasms - blood supply - surgery - ultrastructure |
6 |
|
liver neoplasms - diagnosis - therapy |
6 |
|
liver neoplasms - drug therapy - mortality |
6 |
|
liver neoplasms - drug therapy - pathology - surgery - virology |
6 |
|
liver neoplasms - epidemiology - surgery |
6 |
|
liver neoplasms - etiology - pathology - surgery - virology |
6 |
|
liver neoplasms - genetics - mortality - pathology - surgery - therapy |
6 |
|
liver neoplasms - pathology - radiography - surgery |
6 |
|
liver neoplasms, experimental - drug therapy - metabolism - pathology |
6 |
|
liver neoplasms, experimental - genetics - pathology - prevention and control |
6 |
|
liver neoplasms, experimental - metabolism - pathology - surgery |
6 |
|
liver neoplasms, experimental - metabolism - pathology - virology |
6 |
|
liver transplantation - adverse effects - immunology |
6 |
|
liver transplantation - adverse effects - pathology - physiology |
6 |
|
liver transplantation - pathology |
6 |
|
liver transplantation - pathology - physiology |
6 |
|
liver transplantation - physiology |
6 |
|
liver transplantation - statistics and numerical data |
6 |
|
living |
6 |
|
lung metastasis |
6 |
|
lung neoplasms - etiology - metabolism - secondary |
6 |
|
m2 macrophages |
6 |
|
map kinase signaling system - drug effects |
6 |
|
membrane proteins - genetics - metabolism |
6 |
|
meticillin-resistant staphylococcus aureus |
6 |
|
mitochondria, liver - pathology |
6 |
|
mitogen-activated protein kinase 1 - antagonists & inhibitors - metabolism |
6 |
|
mitogen-activated protein kinase 3 - antagonists & inhibitors - metabolism |
6 |
|
modulation |
6 |
|
molecular sequence data |
6 |
|
mycophenolic acid - administration & dosage - analogs & derivatives |
6 |
|
neoplasm recurrence, local - etiology - metabolism - pathology |
6 |
|
neovascularization, pathologic - prevention & control |
6 |
|
nf-kappa b - metabolism |
6 |
|
nitric oxide synthase - genetics - metabolism |
6 |
|
nitric oxide synthase type iii |
6 |
|
nosocomial transmission |
6 |
|
nucleic acid hybridization |
6 |
|
octreotide - administration & dosage |
6 |
|
oncology |
6 |
|
outcome |
6 |
|
p21/waf1 |
6 |
|
pathologic tumour-node-metastasis (ptnm) stage |
6 |
|
peptidylprolyl isomerase - genetics - metabolism |
6 |
|
phosphatidylinositol 3-kinases - antagonists & inhibitors - metabolism |
6 |
|
phosphatidylinositol 3-kinases - metabolism |
6 |
|
phosphorylation - drug effects |
6 |
|
placebos |
6 |
|
platelet count |
6 |
|
portal pressure - physiology |
6 |
|
probability |
6 |
|
prognostic predictor |
6 |
|
progression |
6 |
|
proline |
6 |
|
prophylaxis |
6 |
|
protein binding |
6 |
|
protein-serine-threonine kinases - metabolism |
6 |
|
proto-oncogene proteins - metabolism |
6 |
|
proto-oncogene proteins c-myc - genetics - metabolism |
6 |
|
ptbd |
6 |
|
rac gtp-binding proteins - chemistry - metabolism |
6 |
|
rac gtp-binding proteins - metabolism |
6 |
|
receptors, interleukin-2 - immunology |
6 |
|
recombinant fusion proteins |
6 |
|
recurrent hepatocellular carcinoma |
6 |
|
reference values |
6 |
|
regional blood flow - physiology |
6 |
|
reperfusion injury - pathology |
6 |
|
reproducibility of results |
6 |
|
right-liver |
6 |
|
risk factor |
6 |
|
rna, small interfering - pharmacology |
6 |
|
serine |
6 |
|
short hairpin rna (shrna) |
6 |
|
six1 |
6 |
|
size |
6 |
|
small-for-size fatty liver |
6 |
|
sorafenib-refractory |
6 |
|
spa type |
6 |
|
standard |
6 |
|
tacrolimus - administration & dosage |
6 |
|
tacrolimus - therapeutic use |
6 |
|
targeted therapy |
6 |
|
therapeutic |
6 |
|
tissue and organ procurement - organization & administration |
6 |
|
tissue distribution |
6 |
|
trans-activators - genetics - metabolism |
6 |
|
transcription factor rela - genetics - metabolism |
6 |
|
transcription, genetic |
6 |
|
transcriptional activation |
6 |
|
transmissibility |
6 |
|
transmission dynamics |
6 |
|
tuberculosis |
6 |
|
tumor markers, biological - blood |
6 |
|
tumor suppressor gene |
6 |
|
tumorigenesis |
6 |
|
vascular endothelial growth factor |
6 |
|
vegf |
6 |
|
waiting lists |
6 |
|
wound healing |
6 |
|
2-de |
5 |
|
academic medical centers |
5 |
|
acute-phase reaction |
5 |
|
acute-phase reaction - metabolism - pathology |
5 |
|
adefovir |
5 |
|
adenosine - chemistry |
5 |
|
adoptive transfer |
5 |
|
adrenal cortex hormones - therapeutic use |
5 |
|
akt survival pathway |
5 |
|
alagille syndrome |
5 |
|
alanine transaminase - analysis |
5 |
|
albumins - genetics - metabolism |
5 |
|
allopurinol - chemistry |
5 |
|
alpha-fetoprotein |
5 |
|
amyloid neuropathies, familial - surgery |
5 |
|
amyloidosis, familial - ethnology - genetics - pathology |
5 |
|
angioplasty - methods |
5 |
|
animal experiment |
5 |
|
animal models |
5 |
|
antibody formation |
5 |
|
antineoplastic agents, hormonal - therapeutic use |
5 |
|
antitubercular agents - pharmacokinetics - therapeutic use |
5 |
|
apolipoprotein c-iii |
5 |
|
apolipoproteins c - metabolism |
5 |
|
asian continental ancestry group |
5 |
|
asian continental ancestry group - genetics |
5 |
|
aspartate aminotransferase |
5 |
|
bile duct atresia |
5 |
|
bile duct obstruction |
5 |
|
bile duct reconstruction |
5 |
|
bile ducts, intrahepatic |
5 |
|
bile leakage |
5 |
|
biomarkers |
5 |
|
biopsy |
5 |
|
biopsy, needle - adverse effects - methods |
5 |
|
blood transfusion, autologous |
5 |
|
bone marrow transplantation - adverse effects |
5 |
|
cancer |
5 |
|
carcinogenicity |
5 |
|
carcinoma - secondary - surgery |
5 |
|
carcinoma, hepatocellular |
5 |
|
carcinoma, hepatocellular - blood - blood supply - pathology |
5 |
|
carcinoma, hepatocellular - blood - diagnosis - surgery |
5 |
|
carcinoma, hepatocellular - blood - surgery |
5 |
|
carcinoma, hepatocellular - chemistry - drug therapy - mortality |
5 |
|
carcinoma, hepatocellular - complications - diagnosis - surgery |
5 |
|
carcinoma, hepatocellular - complications - pathology - surgery |
5 |
|
carcinoma, hepatocellular - drug therapy - pathology - surgery |
5 |
|
carcinoma, hepatocellular - enzymology - pathology - ultrastructure |
5 |
|
carcinoma, hepatocellular - genetics - metabolism |
5 |
|
case-control studies |
5 |
|
catheter ablation - adverse effects |
5 |
|
cause of death |
5 |
|
ccaat-enhancer-binding proteins - physiology |
5 |
|
cell assay |
5 |
|
cell cycle - drug effects |
5 |
|
cell growth |
5 |
|
cell movement - physiology |
5 |
|
cell-free circulating nucleic acid |
5 |
|
chemokine cxcl2 |
5 |
|
chemokines, cxc - metabolism |
5 |
|
chemosensitivity |
5 |
|
chemotherapy, adjuvant |
5 |
|
chi-square distribution |
5 |
|
china - ethnology |
5 |
|
cholangiocarcinoma - complications - pathology - surgery |
5 |
|
cholangiopancreatography, endoscopic retrograde - adverse effects |
5 |
|
cholangiopancreatography, endoscopic retrograde - methods |
5 |
|
cholelithiasis - complications - diagnosis - surgery |
5 |
|
cholestasis, intrahepatic - drug therapy - etiology - surgery |
5 |
|
chromosome aberrations |
5 |
|
clinical competence |
5 |
|
colorectal neoplasms - pathology |
5 |
|
computer systems |
5 |
|
confidence intervals |
5 |
|
cryotherapy |
5 |
|
cytokines - blood - genetics |
5 |
|
diagnosis, differential |
5 |
|
disease transmission, infectious |
5 |
|
dna - chemistry |
5 |
|
dna methylation |
5 |
|
dna primers - chemistry |
5 |
|
dna probes |
5 |
|
dna, complementary - metabolism |
5 |
|
dna, neoplasm - metabolism |
5 |
|
dna, viral - metabolism |
5 |
|
dna-binding proteins - physiology |
5 |
|
docosahexaenoic acid |
5 |
|
docosahexaenoic acids - pharmacology |
5 |
|
donor/recipient origin |
5 |
|
doxorubicin |
5 |
|
dual portal vein |
5 |
|
early growth response protein 1 |
5 |
|
emergency medical services |
5 |
|
endosonography |
5 |
|
endothelial growth factors - blood |
5 |
|
endothelin-1 - blood - genetics |
5 |
|
endothelin-1 - metabolism |
5 |
|
energy metabolism - drug effects - physiology |
5 |
|
enzyme activity |
5 |
|
epidermal growth factor - metabolism |
5 |
|
epithelial-mesenchymal transition - physiology |
5 |
|
evaluation studies as topic |
5 |
|
familial transthyretin amyloidosis |
5 |
|
fibrosis - drug therapy - pathology |
5 |
|
flow cytometry |
5 |
|
focal adhesion kinase 2 - metabolism - physiology |
5 |
|
gallstones - complications - ultrasonography |
5 |
|
glucagon - blood |
5 |
|
glutathione - chemistry |
5 |
|
graft rejection - drug therapy |
5 |
|
graft survival - drug effects - genetics |
5 |
|
graft survival - drug effects - immunology - physiology |
5 |
|
graft survival - physiology |
5 |
|
heat-shock protein |
5 |
|
heat-shock proteins - metabolism |
5 |
|
heme oxygenase (decyclizing) - biosynthesis |
5 |
|
hemostasis |
5 |
|
hemostasis, surgical |
5 |
|
hepatectomy - classification - methods |
5 |
|
hepatic resection |
5 |
|
hepatic steatosis |
5 |
|
hepatic stellate cell (hsc) |
5 |
|
hepatic veins - physiopathology - surgery |
5 |
|
hepatitic decompensation |
5 |
|
hepatitis b - complications - drug therapy - surgery |
5 |
|
hepatitis b - complications - etiology |
5 |
|
hepatitis b - drug therapy - genetics - physiopathology - virology |
5 |
|
hepatitis b antibodies - blood |
5 |
|
hepatitis b core antigens - genetics |
5 |
|
hepatitis b surface antigens - immunology |
5 |
|
hepatitis b virus - drug effects - genetics |
5 |
|
hepatitis b, chronic - blood - pathology - virology |
5 |
|
hepatitis b, chronic - immunology - surgery |
5 |
|
hepatitis b, chronic - surgery |
5 |
|
hepatology |
5 |
|
hsp27 heat-shock proteins |
5 |
|
hsp70 heat-shock proteins - genetics |
5 |
|
human recombinant arginase |
5 |
|
hypertension - epidemiology |
5 |
|
hypertension, portal - etiology - prevention & control |
5 |
|
hypertension, portal - mortality - physiopathology - surgery |
5 |
|
hypoglycemic agents - pharmacology |
5 |
|
hypoxia-inducible factor 1, alpha subunit |
5 |
|
iatrogenic disease |
5 |
|
iatrogenic disease - prevention and control |
5 |
|
immediate-early proteins |
5 |
|
immediate-early proteins - metabolism |
5 |
|
immunosuppressive agents - administration and dosage |
5 |
|
in situ hybridization, fluorescence |
5 |
|
in situ nick-end labeling |
5 |
|
insulin - chemistry - pharmacology |
5 |
|
insulin receptor substrate proteins |
5 |
|
interleukin-10 - biosynthesis |
5 |
|
internal medicine |
5 |
|
intracellular signaling peptides and proteins |
5 |
|
intraoperative complications |
5 |
|
invasion |
5 |
|
kaplan-meier estimate |
5 |
|
ketone bodies - blood |
5 |
|
lamivudine - administration and dosage |
5 |
|
leukemia, myelogenous, chronic, bcr-abl positive - therapy |
5 |
|
live donor liver transplantation |
5 |
|
liver - anatomy & histology - drug effects - ultrastructure |
5 |
|
liver - anatomy & histology - pathology - physiopathology |
5 |
|
liver - anatomy and histology |
5 |
|
liver - chemistry - pathology |
5 |
|
liver - drug effects - injuries - metabolism |
5 |
|
liver - metabolism - ultrastructure |
5 |
|
liver - physiology - surgery |
5 |
|
liver - radiography |
5 |
|
liver cirrhosis - complications - virology |
5 |
|
liver cirrhosis - drug therapy - etiology - surgery |
5 |
|
liver cirrhosis, experimental - surgery |
5 |
|
liver embryo |
5 |
|
liver neoplasms - blood - blood supply - pathology |
5 |
|
liver neoplasms - blood - diagnosis - surgery |
5 |
|
liver neoplasms - blood - secondary - surgery |
5 |
|
liver neoplasms - chemistry - drug therapy - mortality |
5 |
|
liver neoplasms - complications - diagnosis - surgery |
5 |
|
liver neoplasms - complications - mortality - surgery |
5 |
|
liver neoplasms - complications - pathology - surgery |
5 |
|
liver neoplasms - diagnosis - etiology - genetics - surgery |
5 |
|
liver neoplasms - drug therapy - pathology - surgery |
5 |
|
liver neoplasms - enzymology - pathology - ultrastructure |
5 |
|
liver neoplasms - therapy |
5 |
|
liver transplantation - adverse effects - mortality |
5 |
|
liver transplantation - immunology - methods - physiology |
5 |
|
liver transplantation - immunology - mortality - physiology |
5 |
|
liver transplantation - immunology - pathology |
5 |
|
liver transplantation - methods - mortality - statistics & numerical data |
5 |
|
liver transplantation - methods - pathology |
5 |
|
liver transplantation - mortality - physiology - statistics & numerical data |
5 |
|
living related donor |
5 |
|
longitudinal studies |
5 |
|
loss of heterozygosity |
5 |
|
lymphatic metastasis |
5 |
|
lymphocytes - immunology |
5 |
|
lymphokines - blood |
5 |
|
lymphoma, b-cell - etiology - genetics - pathology |
5 |
|
map kinase signaling system |
5 |
|
map kinase signaling system - drug effects - physiology |
5 |
|
mapk |
5 |
|
marrow transplantation |
5 |
|
matrix metalloproteinase-12 |
5 |
|
medical errors - adverse effects |
5 |
|
metachronous primary hcc |
5 |
|
microsatellite analysis |
5 |
|
models, animal |
5 |
|
molecular chaperones - metabolism |
5 |
|
multidrug resistance protein 1 |
5 |
|
mutant |
5 |
|
neoplasm proteins - metabolism |
5 |
|
neoplasm recurrence, local |
5 |
|
neoplasm recurrence, local - blood - diagnosis |
5 |
|
neoplasm recurrence, local - mortality |
5 |
|
neoplasm recurrence, local - mortality - pathology |
5 |
|
neoplasm seeding |
5 |
|
neoplasms, second primary - mortality - surgery |
5 |
|
neovascularization, pathologic |
5 |
|
novel therapy |
5 |
|
nuclear family |
5 |
|
oncofetal proteins |
5 |
|
opportunistic infections - prevention and control |
5 |
|
organ preservation |
5 |
|
organ preservation solutions - chemistry |
5 |
|
organ transplantation - adverse effects - pathology |
5 |
|
orthotopic liver transplantation |
5 |
|
p38 mitogen-activated protein kinases - metabolism |
5 |
|
palliative care - methods |
5 |
|
pancreaticoduodenectomy - mortality - standards |
5 |
|
pancreatitis - etiology - ultrasonography |
5 |
|
pancreatitis, acute necrotizing - diagnosis - etiology - surgery |
5 |
|
pancreatogastrostomy |
5 |
|
paraganglioma |
5 |
|
parenteral nutrition |
5 |
|
phosphoproteins - physiology |
5 |
|
plasma mrna |
5 |
|
point mutation |
5 |
|
portal vein - anatomy and histology - surgery |
5 |
|
portal vein - physiopathology - surgery |
5 |
|
portal vein reconstruction |
5 |
|
post-transplantation lymphoproliferative disorder |
5 |
|
postoperative complications - etiology |
5 |
|
postoperative complications - etiology - pathology |
5 |
|
prealbumin - genetics |
5 |
|
preclinical study |
5 |
|
prediction model |
5 |
|
preoperative care - methods |
5 |
|
proctology |
5 |
|
promoter regions (genetics) |
5 |
|
promoter regions, genetic - genetics |
5 |
|
protein-serine-threonine kinases - physiology |
5 |
|
protein-tyrosine kinases - physiology |
5 |
|
proteins - genetics |
5 |
|
proteins - metabolism |
5 |
|
proteome - metabolism |
5 |
|
proteomic profiling |
5 |
|
proto-oncogene proteins - physiology |
5 |
|
ptk787 |
5 |
|
radiofrequency |
5 |
|
radiography, abdominal |
5 |
|
raf kinases - metabolism |
5 |
|
raffinose - chemistry |
5 |
|
receptors, endothelin - genetics |
5 |
|
receptors, estrogen - analysis |
5 |
|
receptors, progesterone - analysis |
5 |
|
reconstructive surgical procedures - methods |
5 |
|
renal transplantation |
5 |
|
reperfusion injury - drug therapy |
5 |
|
reperfusion injury - metabolism - physiopathology |
5 |
|
residual |
5 |
|
risk assessment |
5 |
|
rna - metabolism |
5 |
|
rna, messenger - analysis |
5 |
|
rna, messenger - blood |
5 |
|
rupture - etiology - mortality - pathology |
5 |
|
safety |
5 |
|
sarcoma - diagnosis - etiology - genetics - surgery |
5 |
|
sepsis |
5 |
|
serologic tests |
5 |
|
severe hepatitis b exacerbation |
5 |
|
sex factors |
5 |
|
signal transduction - drug effects - physiology |
5 |
|
single-blind method |
5 |
|
sirolimus - administration and dosage |
5 |
|
small-for-size graft |
5 |
|
somatostatin - therapeutic use |
5 |
|
spleen - injuries - pathology - radiography - surgery |
5 |
|
statistics, nonparametric |
5 |
|
steroids - therapeutic use |
5 |
|
sterol regulatory element binding protein 1 |
5 |
|
stress, mechanical |
5 |
|
surrogate |
5 |
|
survival rate - trends |
5 |
|
survivin |
5 |
|
tace |
5 |
|
tamoxifen - therapeutic use |
5 |
|
tissue and organ harvesting - methods |
5 |
|
tissue donors - supply & distribution |
5 |
|
toce |
5 |
|
tolerance |
5 |
|
transcription factors - physiology |
5 |
|
transferrin - analysis |
5 |
|
transplantation, homologous - adverse effects |
5 |
|
triptolide |
5 |
|
ttr gene |
5 |
|
tuberculosis - diagnosis - drug therapy - transmission |
5 |
|
tumor necrosis factor-alpha - genetics - metabolism |
5 |
|
up-regulation - physiology |
5 |
|
vascular endothelial growth factor a |
5 |
|
vascular endothelial growth factors |
5 |
|
vasoconstriction - physiology |
5 |
|
virus integration |
5 |
|
ymdd mutation |
5 |
|
ω-3 fatty acids |
5 |
|
" surrogate" end point |
4 |
|
abo blood-group system - immunology |
4 |
|
activated hepatic stellate cells |
4 |
|
active immunization |
4 |
|
adenine - analogs and derivatives - therapeutic use |
4 |
|
adenosine |
4 |
|
alleles |
4 |
|
allopurinol |
4 |
|
anastomosis, surgical - adverse effects |
4 |
|
animal cell |
4 |
|
ann |
4 |
|
antibody against hepatitis b surface antigen |
4 |
|
antigens, cd34 - analysis |
4 |
|
asb4 |
4 |
|
atp7b |
4 |
|
basic fibroblast growth factor |
4 |
|
biliary tract neoplasms - complications - mortality |
4 |
|
biomedical research |
4 |
|
blood group incompatibility - immunology |
4 |
|
blood loss, surgical - statistics & numerical data |
4 |
|
blood vessel prosthesis implantation |
4 |
|
body mass index |
4 |
|
bone marrow cells - pathology |
4 |
|
bregs |
4 |
|
cancer cell |
4 |
|
cancer proteome |
4 |
|
carbon tetrachloride |
4 |
|
carcinoma, hepatocellular - blood - chemistry - diagnosis |
4 |
|
carcinoma, hepatocellular - blood - mortality - pathology - surgery |
4 |
|
carcinoma, hepatocellular - blood supply - immunology |
4 |
|
carcinoma, hepatocellular - classification - pathology - surgery |
4 |
|
carcinoma, hepatocellular - complications - mortality - surgery |
4 |
|
carcinoma, hepatocellular - diagnosis - genetics - metabolism - pathology |
4 |
|
carcinoma, hepatocellular - diagnosis - surgery |
4 |
|
carcinoma, hepatocellular - drug therapy |
4 |
|
carcinoma, hepatocellular - epidemiology - etiology - pathology |
4 |
|
carcinoma, hepatocellular - epidemiology - pathology |
4 |
|
carcinoma, hepatocellular - ethnology - genetics - pathology |
4 |
|
carcinoma, hepatocellular - genetics - mortality |
4 |
|
carcinoma, hepatocellular - genetics - pathology |
4 |
|
carcinoma, hepatocellular - genetics - pathology - surgery |
4 |
|
carcinoma, hepatocellular - genetics - pathology - surgery - virology |
4 |
|
carcinoma, hepatocellular - genetics - pathology - virology |
4 |
|
carcinoma, hepatocellular - metabolism |
4 |
|
carcinoma, hepatocellular - mortality |
4 |
|
carcinoma, hepatocellular - pathology |
4 |
|
carcinoma, hepatocellular - pathology - radiography - surgery |
4 |
|
carcinoma, hepatocellular - pathology - surgery - virology |
4 |
|
carcinoma, hepatocellular - pathology - therapy |
4 |
|
carcinoma, hepatocellular - radiography - surgery |
4 |
|
carrier proteins - metabolism |
4 |
|
cart |
4 |
|
caspase |
4 |
|
catheter ablation - instrumentation - methods |
4 |
|
catheter ablation - standards - statistics & numerical data |
4 |
|
cell hypoxia - drug effects - physiology |
4 |
|
cell line establishment |
4 |
|
cell migration |
4 |
|
cell nucleus - metabolism |
4 |
|
cgh |
4 |
|
cholangiocarcinoma - pathology - surgery |
4 |
|
cholangiocarcinoma - therapy |
4 |
|
cholangiography |
4 |
|
cholangiopancreatography, endoscopic retrograde |
4 |
|
cholangiopancreatography, endoscopic retrograde - methods - mortality |
4 |
|
cholangitis - etiology - surgery |
4 |
|
cholangitis - mortality - therapy |
4 |
|
choledochostomy |
4 |
|
cholestasis - etiology - surgery |
4 |
|
cholestasis - mortality - surgery - therapy |
4 |
|
cholestasis - surgery |
4 |
|
chromosome gain |
4 |
|
chromosomes, human, pair 14 - genetics |
4 |
|
chromosomes, human, y |
4 |
|
classification |
4 |
|
clinical competence - standards - statistics & numerical data |
4 |
|
cluster analysis |
4 |
|
codon |
4 |
|
colonic neoplasms - secondary - surgery |
4 |
|
colonoscopy |
4 |
|
combined hcc-cc |
4 |
|
complications |
4 |
|
contraceptives, oral - administration & dosage |
4 |
|
cox-2 |
4 |
|
cyclooxygenase 2 |
4 |
|
cytotoxicity |
4 |
|
deceased donor |
4 |
|
deoxyribonucleases, type ii site-specific |
4 |
|
discriminant analysis |
4 |
|
dna copy number variations |
4 |
|
dna, neoplasm - genetics |
4 |
|
double-blind method |
4 |
|
drainage |
4 |
|
drug reaction |
4 |
|
drug therapy |
4 |
|
dual graft |
4 |
|
embolization, therapeutic |
4 |
|
end stage liver disease - surgery - virology |
4 |
|
family practice - trends |
4 |
|
fatty change |
4 |
|
fatty liver - pathology - radiography |
4 |
|
female patient |
4 |
|
fibroblast growth factor 2 - blood |
4 |
|
fibrosis progression |
4 |
|
fish |
4 |
|
fluorescent antibody technique |
4 |
|
forecasting |
4 |
|
gallbladder |
4 |
|
gender |
4 |
|
gene expression regulation - drug effects - physiology |
4 |
|
gene frequency |
4 |
|
gene therapy |
4 |
|
gene transfer techniques |
4 |
|
genes, reporter |
4 |
|
genetic heterogeneity |
4 |
|
genotype |
4 |
|
glutathione |
4 |
|
gore-tex graft |
4 |
|
graft occlusion, vascular - diagnosis - etiology - physiopathology - surgery |
4 |
|
graft rejection - drug therapy - pathology |
4 |
|
graft survival - drug effects - physiology |
4 |
|
graft vs host disease - diagnosis - etiology - pathology |
4 |
|
granulin-epithelin precursor |
4 |
|
haemophilus infections |
4 |
|
haplotype |
4 |
|
haplotypes |
4 |
|
hepatectomy - adverse effects - contraindications - methods - mortality |
4 |
|
hepatectomy - adverse effects - methods |
4 |
|
hepatectomy - adverse effects - methods - mortality |
4 |
|
hepatectomy - adverse effects - mortality - standards |
4 |
|
hepatectomy - statistics and numerical data |
4 |
|
hepatic artery ligation |
4 |
|
hepatic veins - pathology |
4 |
|
hepatic veins - physiopathology |
4 |
|
hepatic veins - physiopathology - radiography - surgery |
4 |
|
hepatitis b - complications - pathology - surgery |
4 |
|
hepatitis b - prevention & control - surgery - therapy |
4 |
|
hepatitis b antibodies - analysis |
4 |
|
hepatitis b e antigens - analysis |
4 |
|
hepatitis b infection |
4 |
|
hepatitis b vaccines - therapeutic use |
4 |
|
hepatitis b virus - genetics - immunology |
4 |
|
hepatitis b virus - isolation & purification |
4 |
|
hepatitis b, chronic - drug therapy - pathology - virology |
4 |
|
hepatitis b, chronic - etiology - immunology - prevention & control |
4 |
|
hepatitis, chronic - complications - surgery |
4 |
|
hepatoblastoma |
4 |
|
hepatoblastoma - epidemiology - pathology |
4 |
|
hepatocytes - drug effects - metabolism |
4 |
|
hepatolenticular degeneration - genetics |
4 |
|
hepatotoxicity |
4 |
|
hernia - etiology |
4 |
|
hif-1α |
4 |
|
histocompatibility testing |
4 |
|
histology |
4 |
|
hla |
4 |
|
hla antigens - analysis |
4 |
|
homeostasis - physiology |
4 |
|
hsp70 heat-shock proteins - chemistry - genetics - metabolism |
4 |
|
hsp70 heat-shock proteins - genetics - metabolism |
4 |
|
hypertension, portal - complications - surgery |
4 |
|
hypoxic t6-hscs |
4 |
|
image interpretation, computer-assisted |
4 |
|
immunity |
4 |
|
immunization |
4 |
|
immunocompromised patient |
4 |
|
immunosuppression |
4 |
|
immunosuppression - methods |
4 |
|
indocyanine green - diagnostic use |
4 |
|
indomethacin - pharmacology |
4 |
|
inoperable |
4 |
|
insulin - pharmacology |
4 |
|
intercellular signaling peptides and proteins - genetics |
4 |
|
interferon-gamma |
4 |
|
interleukin-6 - genetics - metabolism |
4 |
|
internal hernia |
4 |
|
intestinal diseases - etiology - surgery |
4 |
|
intestinal obstruction |
4 |
|
intestinal obstruction - etiology - surgery |
4 |
|
intolerance |
4 |
|
intrahepatic metastasis |
4 |
|
iodide peroxidase - genetics |
4 |
|
ischemic injury |
4 |
|
isoenzymes - antagonists & inhibitors - metabolism |
4 |
|
kasai portoenterostomy |
4 |
|
kupffer cells - cytology |
4 |
|
laparoscopic cholecystectomy |
4 |
|
laparoscopic ultrasonography |
4 |
|
laparoscopy - statistics and numerical data |
4 |
|
large |
4 |
|
linkage disequilibrium |
4 |
|
lipid peroxidation |
4 |
|
live donor |
4 |
|
liver - drug effects - pathology |
4 |
|
liver - pathology - radiography - surgery |
4 |
|
liver - surgery |
4 |
|
liver circulation |
4 |
|
liver circulation - drug effects |
4 |
|
liver cirrhosis - complications - surgery |
4 |
|
liver cirrhosis - diagnosis - surgery |
4 |
|
liver cirrhosis - epidemiology - etiology - pathology |
4 |
|
liver complications |
4 |
|
liver failure |
4 |
|
liver fibrosis |
4 |
|
liver graft |
4 |
|
liver injury |
4 |
|
liver neoplasm |
4 |
|
liver neoplasms - blood - chemistry - diagnosis |
4 |
|
liver neoplasms - blood - mortality - pathology - surgery |
4 |
|
liver neoplasms - blood supply - immunology |
4 |
|
liver neoplasms - classification - mortality - pathology - surgery |
4 |
|
liver neoplasms - diagnosis - genetics - metabolism - pathology |
4 |
|
liver neoplasms - diagnosis - surgery |
4 |
|
liver neoplasms - drug therapy |
4 |
|
liver neoplasms - epidemiology - etiology - pathology |
4 |
|
liver neoplasms - epidemiology - pathology |
4 |
|
liver neoplasms - ethnology - genetics - pathology |
4 |
|
liver neoplasms - genetics - metabolism |
4 |
|
liver neoplasms - genetics - metabolism - pathology - secondary |
4 |
|
liver neoplasms - genetics - mortality |
4 |
|
liver neoplasms - genetics - pathology |
4 |
|
liver neoplasms - genetics - pathology - secondary - virology |
4 |
|
liver neoplasms - genetics - pathology - surgery |
4 |
|
liver neoplasms - genetics - pathology - surgery - virology |
4 |
|
liver neoplasms - metabolism |
4 |
|
liver neoplasms - metabolism - pathology - surgery |
4 |
|
liver neoplasms - mortality |
4 |
|
liver neoplasms - pathology - surgery - virology |
4 |
|
liver neoplasms - pathology - therapy |
4 |
|
liver neoplasms - radiography - surgery |
4 |
|
liver neoplasms - secondary - therapy |
4 |
|
liver neoplasms - surgery - therapy |
4 |
|
liver transplantation - immunology - methods |
4 |
|
liver tumors |
4 |
|
living donor transplantation |
4 |
|
living donors - psychology - supply and distribution |
4 |
|
loh |
4 |
|
luciferases - metabolism |
4 |
|
lymphocytes - pathology |
4 |
|
macrophage activation - immunology |
4 |
|
macrophages - cytology |
4 |
|
member d |
4 |
|
membrane proteins - genetics |
4 |
|
mhc class i chain-related molecule a |
4 |
|
micrornas - genetics - metabolism |
4 |
|
migration |
4 |
|
mir-200a |
4 |
|
mixed tumor, malignant - pathology - surgery |
4 |
|
modified hai score |
4 |
|
molecular relationship |
4 |
|
multicentric occurrence |
4 |
|
multigene family |
4 |
|
multinodular |
4 |
|
natural-killer group 2 |
4 |
|
neoplasm proteins - analysis - blood |
4 |
|
neoplasm recurrence, local - blood supply |
4 |
|
neoplasm recurrence, local - diagnosis - genetics - pathology |
4 |
|
neoplasm recurrence, local - mortality - pathology - surgery |
4 |
|
neoplasm recurrence, local - pathology - surgery |
4 |
|
neoplastic stem cells - pathology |
4 |
|
nf-kappa b - biosynthesis |
4 |
|
nitric oxide |
4 |
|
novel mutation |
4 |
|
nucleic acid hybridization - methods |
4 |
|
nutritional support |
4 |
|
occult hbv co-infection |
4 |
|
octreotide |
4 |
|
organ donation |
4 |
|
organ preservation - methods |
4 |
|
organ preservation solutions |
4 |
|
oxidative stress |
4 |
|
p.r778l founder mutation |
4 |
|
p27 |
4 |
|
pancreatic anastomotic leakage |
4 |
|
pancreatic neoplasms - complications |
4 |
|
pattern |
4 |
|
pdgf-bb |
4 |
|
perforin |
4 |
|
phenotype |
4 |
|
phlebography - methods |
4 |
|
phosphonic acids - therapeutic use |
4 |
|
pi3-kinase/akt |
4 |
|
plasmids - metabolism |
4 |
|
pneumococcal infections |
4 |
|
portal vein - pathology - radiography - surgery |
4 |
|
portal vein invasion |
4 |
|
postoperative complications - epidemiology - mortality |
4 |
|
preventive medicine - methods |
4 |
|
primary liver tumours |
4 |
|
pringle manoeuvre |
4 |
|
prostaglandin-endoperoxide synthases - metabolism |
4 |
|
protein array analysis |
4 |
|
protein-losing enteropathies - etiology - surgery |
4 |
|
proteome - analysis - chemistry |
4 |
|
proteomics - methods - trends |
4 |
|
proto-oncogene proteins c-met - genetics |
4 |
|
raffinose |
4 |
|
reactive oxygen species |
4 |
|
recurrence - prevention & control |
4 |
|
recurrent chronic hepatitis c virus |
4 |
|
relapsed infection due to hbv |
4 |
|
reperfusion injury - physiopathology |
4 |
|
resectability |
4 |
|
retreatment |
4 |
|
rhoa-gtp |
4 |
|
right liver graft |
4 |
|
roc curve |
4 |
|
ruptured hepatocellular carcinoma |
4 |
|
sequence analysis, dna |
4 |
|
severe fibrosis |
4 |
|
signal transduction - physiology |
4 |
|
single institution |
4 |
|
skin - pathology |
4 |
|
small-for size graft |
4 |
|
split graft |
4 |
|
steatotic donor |
4 |
|
streptococcal infections |
4 |
|
stress |
4 |
|
sulfonamides - pharmacology |
4 |
|
surgical procedures, operative |
4 |
|
swine |
4 |
|
tandem mass spectrometry |
4 |
|
tissue and organ harvesting - adverse effects - methods |
4 |
|
tissue and organ harvesting - adverse effects - mortality - standards |
4 |
|
tnp-470 |
4 |
|
trans-activators - biosynthesis |
4 |
|
transarterial embolization |
4 |
|
transcriptome |
4 |
|
transplant outcomes |
4 |
|
transplant research |
4 |
|
transplantation chimera |
4 |
|
tumor biomarker |
4 |
|
tumor markers, biological - analysis |
4 |
|
tumor markers, biological - analysis - blood |
4 |
|
tumor markers, biological - genetics |
4 |
|
tumor rupture |
4 |
|
tumor suppressor protein p53 - biosynthesis - genetics |
4 |
|
ultrastructure |
4 |
|
urokinase-type plasminogen activator - biosynthesis |
4 |
|
urology and nephrology |
4 |
|
vein graft |
4 |
|
vena cava, inferior - surgery |
4 |
|
vhl |
4 |
|
wilson disease |
4 |
|
y chromosome - genetics |
4 |
|
β-hydroxyl |
4 |
|
γ-butyrolactone |
4 |
|
aa454543 |
3 |
|
actuarial analysis |
3 |
|
adaptor proteins, signal transducing |
3 |
|
adenosine - pharmacology |
3 |
|
adenosine triphosphate - analysis |
3 |
|
adrenomedullin |
3 |
|
adrenomedullin - genetics - metabolism |
3 |
|
age |
3 |
|
algorithms |
3 |
|
allograft inflammatory factor-1 |
3 |
|
alpha-fetoproteins - analysis |
3 |
|
alternative splicing |
3 |
|
aminopyrine - diagnostic use |
3 |
|
aminopyrine breath test |
3 |
|
angiogenesis inducing agents - metabolism |
3 |
|
angiogenesis inhibitors - therapeutic use |
3 |
|
angiogenic factor |
3 |
|
antineoplastic activity |
3 |
|
antineoplastic combined chemotherapy protocols - administration & dosage |
3 |
|
atp-binding cassette transporters - physiology |
3 |
|
attitude of health personnel |
3 |
|
autopsy |
3 |
|
axl receptor kinase |
3 |
|
bacterial infections |
3 |
|
berberine |
3 |
|
beta-galactosidase - metabolism |
3 |
|
bias (epidemiology) |
3 |
|
bile |
3 |
|
bile duct neoplasms - radiotherapy |
3 |
|
bile ducts - metabolism - surgery |
3 |
|
bile ducts - pathology - surgery |
3 |
|
bile ducts, intrahepatic - pathology |
3 |
|
bile ducts, intrahepatic - surgery |
3 |
|
biliary obstruction |
3 |
|
biliary tract - abnormalities - radiography |
3 |
|
biliary tract diseases - etiology |
3 |
|
biliary tract diseases - etiology - therapy |
3 |
|
biliary tract neoplasms - therapy |
3 |
|
biliary tract surgical procedures - adverse effects |
3 |
|
biological markers - blood |
3 |
|
bleeding |
3 |
|
blood glucose - analysis |
3 |
|
blood loss, surgical - physiopathology |
3 |
|
blood sampling |
3 |
|
body surface area |
3 |
|
brachytherapy |
3 |
|
brain-derived neurotrophic factor |
3 |
|
breath tests |
3 |
|
cadherins |
3 |
|
calcitonin receptor |
3 |
|
calcitonin receptor-like protein |
3 |
|
calcium - diagnostic use |
3 |
|
cancer signaling |
3 |
|
cancer stem cells |
3 |
|
capture |
3 |
|
carbon tetrachloride - toxicity |
3 |
|
carcinogenesis |
3 |
|
carcinoma, hepatocellular - blood - diagnosis - pathology - therapy |
3 |
|
carcinoma, hepatocellular - blood - mortality |
3 |
|
carcinoma, hepatocellular - blood supply - pathology - surgery |
3 |
|
carcinoma, hepatocellular - complications - drug therapy - metabolism |
3 |
|
carcinoma, hepatocellular - epidemiology - genetics - pathology |
3 |
|
carcinoma, hepatocellular - genetics - metabolism - mortality |
3 |
|
carcinoma, hepatocellular - genetics - metabolism - mortality - pathology |
3 |
|
carcinoma, hepatocellular - genetics - metabolism - physiopathology |
3 |
|
carcinoma, hepatocellular - genetics - virology |
3 |
|
carcinoma, hepatocellular - metabolism - therapy |
3 |
|
carcinoma, hepatocellular - mortality - pathology - surgery - therapy |
3 |
|
carcinoma, hepatocellular - mortality - pathology - virology |
3 |
|
carcinoma, hepatocellular - pathology - physiopathology - surgery |
3 |
|
carcinoma, hepatocellular - pathology - surgery - ultrasonography |
3 |
|
carcinoma, hepatocellular - secondary - surgery |
3 |
|
carrier proteins - biosynthesis |
3 |
|
catcinoma |
3 |
|
catheterization, central venous |
3 |
|
celastrol |
3 |
|
cell count |
3 |
|
cell division |
3 |
|
cell survival - physiology |
3 |
|
cellular retinol binding protein |
3 |
|
chilaiditi's sign |
3 |
|
cholangiocarcinoma - complications - mortality - surgery |
3 |
|
cholangiocarcinoma - radiotherapy |
3 |
|
cholangitis |
3 |
|
cholangitis-therapy |
3 |
|
cholecystectomy, laparoscopic - adverse effects |
3 |
|
cholecystitis - surgery - ultrasonography |
3 |
|
cholelithiasis - diagnosis - therapy |
3 |
|
cholelithiasis - surgery - therapy |
3 |
|
cholestasis - epidemiology - metabolism - surgery |
3 |
|
cholestasis - physiopathology - surgery |
3 |
|
chromosome 8p |
3 |
|
chromosome deletion |
3 |
|
chromosomes, human, pair 13 - genetics |
3 |
|
chromosomes, human, pair 8 |
3 |
|
circulating tumor cell |
3 |
|
cisplatin - administration & dosage |
3 |
|
clinical trials as topic |
3 |
|
clinicopathologic correlation |
3 |
|
clinicopathologic correlation and prognostication |
3 |
|
colon - radiography |
3 |
|
colorectal neoplasms - secondary |
3 |
|
constriction, pathologic |
3 |
|
copy number variation |
3 |
|
cost-benefit analysis |
3 |
|
cost-effective |
3 |
|
ctla4ig |
3 |
|
curcumin |
3 |
|
cysteine - analogs and derivatives - pharmacology - therapeutic use |
3 |
|
cytochrome p-450 cyp2e1 - biosynthesis - pharmacology |
3 |
|
cytochrome p450 |
3 |
|
cytoskeletal proteins - antagonists & inhibitors |
3 |
|
cytoskeletal proteins - biosynthesis - genetics |
3 |
|
dapper |
3 |
|
deceased-donor |
3 |
|
delayed coincidence timing |
3 |
|
dendritic cells - pathology |
3 |
|
diabetes complications |
3 |
|
diagnostic errors |
3 |
|
diaphragm - radiography |
3 |
|
differential expression |
3 |
|
disease marker |
3 |
|
distal pancreatectomy |
3 |
|
dna, complementary |
3 |
|
dna, neoplasm - analysis |
3 |
|
drainage-methods |
3 |
|
drug resistance, neoplasm - physiology |
3 |
|
duodenal |
3 |
|
duodenal diseases - etiology |
3 |
|
duodenopleutal |
3 |
|
electrodes |
3 |
|
embolization, therapeutic - methods |
3 |
|
emt |
3 |
|
endoscopy |
3 |
|
endoscopy,-gastrointestinal |
3 |
|
endothelial growth factors - biosynthesis - genetics |
3 |
|
endothelial growth factors - genetics - metabolism |
3 |
|
endothelial growth factors - metabolism |
3 |
|
enucleation |
3 |
|
epidemiologic factors |
3 |
|
equipment design |
3 |
|
essential thrombocythemia |
3 |
|
estimated standard liver weight |
3 |
|
extracellular matrix proteins - genetics - metabolism |
3 |
|
feasibility studies |
3 |
|
fistula |
3 |
|
flk-1/kdr |
3 |
|
flowmetry |
3 |
|
flt-1 |
3 |
|
follicular dendritic cell |
3 |
|
fulminant hepatic failure |
3 |
|
gallstones-surgery |
3 |
|
garlic - chemistry |
3 |
|
gastrointestinal neoplasms - blood supply - drug therapy - metabolism |
3 |
|
gene silencing |
3 |
|
gene therapy - methods |
3 |
|
genes, p16 |
3 |
|
genetic markers - genetics |
3 |
|
genomic rearrangement |
3 |
|
glucose - pharmacology |
3 |
|
glycyrrhetinic acid |
3 |
|
glycyrrhizin |
3 |
|
graft shortage |
3 |
|
graft survival - immunology |
3 |
|
guidelines |
3 |
|
haematoma |
3 |
|
hdpr1 |
3 |
|
hemagglutinins - metabolism |
3 |
|
hemostasis, surgical - methods |
3 |
|
hepatectomy - instrumentation - methods |
3 |
|
hepatectomy - mortality |
3 |
|
hepatic |
3 |
|
hepatic artery |
3 |
|
hepatic duct, common - pathology |
3 |
|
hepatic duct, common - surgery |
3 |
|
hepatic veins |
3 |
|
hepatic veins - transplantation |
3 |
|
hepatitis b |
3 |
|
hepatitis b - pathology |
3 |
|
hepatitis b - surgery |
3 |
|
hepatitis b antigens - metabolism |
3 |
|
hepatitis b virus - physiology |
3 |
|
hepatitis, chronic - pathology - surgery |
3 |
|
hepatolithiasis |
3 |
|
hevin |
3 |
|
high-throughput |
3 |
|
hilar cholangiocarcinoma |
3 |
|
hippo pathway |
3 |
|
histologic activity index |
3 |
|
hormones - administration & dosage |
3 |
|
hyperalimentation |
3 |
|
immunoenzyme techniques |
3 |
|
in situ hybridization |
3 |
|
indocyanine green retention |
3 |
|
inflammatory pseudotumour |
3 |
|
insulin - blood |
3 |
|
insulinoma - diagnosis - surgery |
3 |
|
insulinoma - pathology - surgery |
3 |
|
integration |
3 |
|
intensive care |
3 |
|
intercellular signaling peptides and proteins - biosynthesis |
3 |
|
intercellular signaling peptides and proteins - biosynthesis - genetics |
3 |
|
intercellular signaling peptides and proteins - physiology |
3 |
|
interleukin-8 - biosynthesis - genetics |
3 |
|
interstitial laser therapy |
3 |
|
intestinal fistula - etiology |
3 |
|
intestinal perforation - radiography |
3 |
|
intracellular signaling peptides and proteins - genetics - metabolism |
3 |
|
intramural |
3 |
|
intraoperative complications - etiology |
3 |
|
intraoperative complications - etiology - prevention & control |
3 |
|
intraoperative period |
3 |
|
jak2 |
3 |
|
janus kinase 2 - genetics |
3 |
|
jejunostomy - methods |
3 |
|
jnk signaling |
3 |
|
kasai operation |
3 |
|
laparotomy |
3 |
|
li-cadherin |
3 |
|
linear models |
3 |
|
lithiasis - complications - surgery |
3 |
|
liver - blood supply |
3 |
|
liver - blood supply - surgery |
3 |
|
liver - pathology - surgery |
3 |
|
liver - physiology |
3 |
|
liver -- surgery. |
3 |
|
liver cirrhosis - pathology |
3 |
|
liver cirrhosis - pathology - surgery |
3 |
|
liver cirrhosis, experimental - chemically induced |
3 |
|
liver diseases - complications - surgery |
3 |
|
liver diseases - genetics - pathology |
3 |
|
liver diseases - pathology - physiopathology - surgery |
3 |
|
liver failure - etiology |
3 |
|
liver failure - radiography |
3 |
|
liver failure - surgery - therapy |
3 |
|
liver neoplasms - blood - mortality |
3 |
|
liver neoplasms - blood supply - pathology - surgery |
3 |
|
liver neoplasms - complications - drug therapy - metabolism |
3 |
|
liver neoplasms - epidemiology - genetics - pathology |
3 |
|
liver neoplasms - genetics - metabolism - mortality |
3 |
|
liver neoplasms - genetics - metabolism - mortality - pathology |
3 |
|
liver neoplasms - genetics - metabolism - physiopathology |
3 |
|
liver neoplasms - genetics - virology |
3 |
|
liver neoplasms - metabolism - therapy |
3 |
|
liver neoplasms - mortality - pathology - surgery - therapy |
3 |
|
liver neoplasms - mortality - pathology - virology |
3 |
|
liver neoplasms - pathology - surgery - ultrasonography |
3 |
|
liver regeneration - physiology |
3 |
|
liver transplantation - contraindications - methods |
3 |
|
liver transplantation - immunology - methods - mortality |
3 |
|
liver transplantation - methods - psychology |
3 |
|
liver tumor |
3 |
|
livercancer |
3 |
|
living donors - history |
3 |
|
living donors - psychology |
3 |
|
lymphangioma |
3 |
|
lymphangioma - epidemiology - pathology - surgery |
3 |
|
lymphokines - biosynthesis - genetics |
3 |
|
lymphokines - genetics - metabolism |
3 |
|
lymphokines - metabolism |
3 |
|
lymphoma, follicular - pathology - radiography - surgery |
3 |
|
m6p26-hsa |
3 |
|
macrophage migration inhibitory factor |
3 |
|
macrophage migration-inhibitory factors - pharmacology - physiology |
3 |
|
macrophages |
3 |
|
macrophages - immunology |
3 |
|
malignancy |
3 |
|
malignant liver tumor |
3 |
|
membrane transport proteins |
3 |
|
micrornas - genetics |
3 |
|
microscopy, fluorescence |
3 |
|
microvascular surgery |
3 |
|
microvessel density |
3 |
|
microwave coagulation therapy |
3 |
|
molecular targeted therapy |
3 |
|
multiple endocrine neoplasia type 1 - surgery |
3 |
|
mutations |
3 |
|
neoplasm recurrence, local - prevention & control - therapy |
3 |
|
neoplasm recurrence, local - therapy |
3 |
|
neoplasm transplantation |
3 |
|
neoplasms - metabolism - mortality - therapy |
3 |
|
neoplasms - pathology |
3 |
|
neovascularization, pathologic - blood - diagnosis |
3 |
|
nitrates - metabolism |
3 |
|
nitrites - metabolism |
3 |
|
notch signaling |
3 |
|
nuclear accumulation |
3 |
|
nuclear proteins - genetics - metabolism |
3 |
|
nuclear proteins - genetics - physiology |
3 |
|
obstructive jaundice |
3 |
|
octamer transcription factor-3 - physiology |
3 |
|
oligopeptides - metabolism |
3 |
|
organ culture techniques |
3 |
|
organ preservation solutions - pharmacology |
3 |
|
origin |
3 |
|
overexpression |
3 |
|
oxymatrine |
3 |
|
p-glycoprotein |
3 |
|
p53: hepatocellular carcinoma |
3 |
|
pancreas |
3 |
|
pancreas - pathology |
3 |
|
pancreatic |
3 |
|
pancreatic insulinoma |
3 |
|
pancreatic neoplasms - diagnosis - surgery |
3 |
|
pancreatic neoplasms - epidemiology - pathology - surgery |
3 |
|
pancreatic neoplasms - pathology - surgery |
3 |
|
pancreatic pseudocyst - diagnosis |
3 |
|
pancreatitis - blood - etiology - prevention & control |
3 |
|
pancreatitis - blood - mortality |
3 |
|
pancreatitis-surgery |
3 |
|
platelet |
3 |
|
platelet apheresis |
3 |
|
pleural diseases - etiology |
3 |
|
polymorphism |
3 |
|
portal inflow |
3 |
|
portal vein thrombosis |
3 |
|
portoenterostomy |
3 |
|
postoperative complications - epidemiology - prevention & control |
3 |
|
postoperative complications - etiology - therapy |
3 |
|
postoperative complications - radiography - therapy |
3 |
|
postoperative period |
3 |
|
potassium chloride - pharmacology |
3 |
|
prognostic factors |
3 |
|
promoter regions, genetic |
3 |
|
protein isoforms - metabolism |
3 |
|
protein-tyrosine kinases - antagonists & inhibitors |
3 |
|
proto-oncogene proteins - genetics - metabolism |
3 |
|
ptnm classification |
3 |
|
quality of life |
3 |
|
questionnaires |
3 |
|
raffinose - pharmacology |
3 |
|
ramp |
3 |
|
receptor activity-modifying protein 1 |
3 |
|
receptor activity-modifying protein 2 |
3 |
|
receptor activity-modifying protein 3 |
3 |
|
receptor activity-modifying proteins |
3 |
|
receptor protein-tyrosine kinases - genetics - metabolism |
3 |
|
receptor, epidermal growth factor - genetics - metabolism |
3 |
|
receptor-mediated gene transfer system |
3 |
|
receptors, calcitonin - genetics - metabolism |
3 |
|
receptors, growth factor - genetics - metabolism |
3 |
|
receptors, vascular endothelial growth factor |
3 |
|
regional blood flow/physiology |
3 |
|
regression analysis |
3 |
|
renal veins - surgery - ultrasonography |
3 |
|
renin - blood |
3 |
|
respiratory tract fistula - etiology |
3 |
|
responses |
3 |
|
retinol-binding proteins - metabolism |
3 |
|
retinol-binding proteins, cellular - metabolism |
3 |
|
retroviridae - genetics |
3 |
|
retrovirus |
3 |
|
right liver |
3 |
|
rna, neoplasm - genetics - isolation & purification |
3 |
|
rna, neoplasm - metabolism |
3 |
|
rupture, spontaneous |
3 |
|
salvianolic acids |
3 |
|
saphenous vein - surgery |
3 |
|
sequence deletion |
3 |
|
sequence homology, amino acid |
3 |
|
signalling |
3 |
|
simplifying |
3 |
|
smyd3 |
3 |
|
sodium chloride |
3 |
|
somatostatin - administration & dosage |
3 |
|
sonoluminescence |
3 |
|
sparc |
3 |
|
sphincterotomy, endoscopic - adverse effects - mortality - statistics & numerical data |
3 |
|
sphincterotomy,-endoscopic-adverse-effects |
3 |
|
sphincterotomy,-endoscopic-mortality |
3 |
|
splanchnic circulation - physiology |
3 |
|
splenic artery |
3 |
|
splenic vein - surgery - ultrasonography |
3 |
|
spouses |
3 |
|
stellate cells |
3 |
|
subcapsular carcinoma |
3 |
|
subclavian vein - surgery |
3 |
|
subphrenic abscess - radiography |
3 |
|
surgical approaches |
3 |
|
surgical procedures, elective |
3 |
|
systemic |
3 |
|
t lymphocyte function |
3 |
|
temperature |
3 |
|
tetrandrine |
3 |
|
thermal ablative therapy |
3 |
|
thrombocytosis |
3 |
|
thrombocytosis - genetics |
3 |
|
thymidine phosphorylase - blood |
3 |
|
tissue and organ harvesting |
3 |
|
tissue and organ procurement - methods |
3 |
|
tissue and organ procurement - statistics and numerical data |
3 |
|
tissue culture techniques |
3 |
|
tissue donors - supply and distributionhttp://hub.hku.hk/tools/edit-item |
3 |
|
trans-activators |
3 |
|
trans-activators - antagonists & inhibitors |
3 |
|
transforming growth factor beta - blood |
3 |
|
transplantation, liver |
3 |
|
transplants - standards |
3 |
|
tumor cells, cultured - metabolism - pathology |
3 |
|
tumor markers, biological |
3 |
|
tumor markers, biological - biosynthesis - genetics |
3 |
|
tumor recurrence |
3 |
|
type i collagen |
3 |
|
ultrasonography, interventional |
3 |
|
urea - blood |
3 |
|
vascular endothelial growth factor a - biosynthesis - immunology |
3 |
|
vascular endothelial growth factor receptor-1 |
3 |
|
vascular endothelial growth factor receptor-2 - biosynthesis - immunology |
3 |
|
venoplasty |
3 |
|
venous thrombosis - etiology |
3 |
|
viral infections |
3 |
|
whole-genome sequencing |
3 |
|
wnt proteins |
3 |
|
wnt/β-catenin signaling |
3 |
|
yap1 oncogene |
3 |
|
3-hydroxybutyric acid |
2 |
|
abo blood-group system - adverse effects |
2 |
|
abscess - radiography |
2 |
|
aclf |
2 |
|
acrogranin |
2 |
|
acute cholecystitis |
2 |
|
acute pancreatitis |
2 |
|
acute-on-chronicliver disease |
2 |
|
adeno-associated virus |
2 |
|
adenocarcinoma - complications - pathology - secondary |
2 |
|
adenoma, bile duct - etiology - therapy |
2 |
|
adenosinetriphosphatase/genetics |
2 |
|
adrenal gland neoplasms - complications - diagnosis - surgery |
2 |
|
alanine - genetics |
2 |
|
albumin |
2 |
|
aldehyde reductase - genetics |
2 |
|
ambulatory surgical procedures |
2 |
|
ampulla of vater |
2 |
|
amyloid |
2 |
|
amyloid neuropathies - genetics |
2 |
|
anastomosis, roux-en-y - standards |
2 |
|
angiography |
2 |
|
angiomyolipoma - pathology - radiography |
2 |
|
angiostatin |
2 |
|
animals, laboratory |
2 |
|
anti-inflammatory agents, non-steroidal - pharmacology |
2 |
|
antibodies, monoclonal |
2 |
|
antibodies, monoclonal - diagnostic use |
2 |
|
antigens, cd |
2 |
|
antigens, cd - metabolism |
2 |
|
antigens, cd18 - chemistry - genetics - metabolism |
2 |
|
antigens, differentiation - genetics - immunology |
2 |
|
antigens, neoplasm - analysis - genetics |
2 |
|
antineoplastic agents - administration and dosage |
2 |
|
antineoplastic combined chemotherapy protocols - therapeutic use |
2 |
|
appendectomy |
2 |
|
appendicitis - surgery |
2 |
|
auxiliary liver transplantation |
2 |
|
b7.1 |
2 |
|
bacterial infections - pathology - radiography - surgery - ultrasonography |
2 |
|
bile duct diseases - complications |
2 |
|
bile duct diseases - therapy |
2 |
|
bile duct neoplasms - etiology - therapy |
2 |
|
bile duct neoplasms - radiography - surgery |
2 |
|
bile duct neoplasms - surgery |
2 |
|
bile ducts, intrahepatic - radiography |
2 |
|
biliary anastomosis |
2 |
|
biliary pancreatitis |
2 |
|
biliary tract surgical procedures - standards |
2 |
|
binding sites |
2 |
|
biology |
2 |
|
biomarker |
2 |
|
blood banks |
2 |
|
blood coagulation tests |
2 |
|
blood grouping and crossmatching |
2 |
|
blood pressure |
2 |
|
blood transfusion - utilization |
2 |
|
bone marrow |
2 |
|
bone marrow stromal cells |
2 |
|
brain derived neurotrophic factor |
2 |
|
caffeine - pharmacology |
2 |
|
calculi - complications - physiopathology - surgery |
2 |
|
calculi - mortality - surgery |
2 |
|
cancer patient |
2 |
|
cancer stem cell |
2 |
|
capsular thickness |
2 |
|
carcinoma, hepatocellular - blood - complications - mortality - surgery |
2 |
|
carcinoma, hepatocellular - blood supply - mortality - therapy |
2 |
|
carcinoma, hepatocellular - complications - pathology |
2 |
|
carcinoma, hepatocellular - complications - radiography |
2 |
|
carcinoma, hepatocellular - diagnosis |
2 |
|
carcinoma, hepatocellular - diagnosis - epidemiology - surgery |
2 |
|
carcinoma, hepatocellular - drug therapy - metabolism |
2 |
|
carcinoma, hepatocellular - drug therapy - metabolism - mortality |
2 |
|
carcinoma, hepatocellular - drug therapy - metabolism - pathology |
2 |
|
carcinoma, hepatocellular - drug therapy - pathology |
2 |
|
carcinoma, hepatocellular - genetics - immunology - pathology |
2 |
|
carcinoma, hepatocellular - immunology - mortality - pathology |
2 |
|
carcinoma, hepatocellular - mortality - pathology |
2 |
|
carcinoma, hepatocellular - mortality - pathology - surgery - virology |
2 |
|
carcinoma, hepatocellular - ultrasonography |
2 |
|
cardiopulmonary bypass |
2 |
|
cardiotrophin-1 |
2 |
|
case report |
2 |
|
caspase 3 |
2 |
|
caspases - metabolism |
2 |
|
catheterization, peripheral |
2 |
|
cell cycle proteins - metabolism - radiation effects |
2 |
|
cell hypoxia |
2 |
|
cell invasion |
2 |
|
cell nucleus - immunology - ultrastructure |
2 |
|
cell selection |
2 |
|
cell transplantation |
2 |
|
cellcycle |
2 |
|
cellular differentiation |
2 |
|
cellular response |
2 |
|
ceruloplasmin |
2 |
|
ceruloplasmin - metabolism |
2 |
|
chemoembolization, therapeutic - adverse effects - methods |
2 |
|
chemoembolization, therapeutic - methods |
2 |
|
chemokine receptor |
2 |
|
cholangiocellular carcinoma |
2 |
|
cholangiopancreatography, endoscopic retrograde - adverse effects - mortality |
2 |
|
cholangitis - complications - metabolism - mortality - surgery |
2 |
|
cholangitis - complications - radiography |
2 |
|
cholangitis - etiology |
2 |
|
cholangitis - etiology - physiopathology - surgery |
2 |
|
cholangitis - etiology - therapy |
2 |
|
cholangitis - microbiology - mortality - therapy |
2 |
|
cholangitis - pathology - radiography - surgery - ultrasonography |
2 |
|
cholecystectomy, laparoscopic |
2 |
|
choledochal cyst |
2 |
|
cholelithiasis - complications |
2 |
|
cholelithiasis - complications - epidemiology |
2 |
|
cholelithiasis - complications - radiography |
2 |
|
cholelithiasis - therapy |
2 |
|
cholestasis, extrahepatic - diagnosis - etiology |
2 |
|
cholestasis, intrahepatic - complications - radiography |
2 |
|
cholestasis, intrahepatic - etiology - surgery |
2 |
|
cholestasis, intrahepatic - etiology - therapy |
2 |
|
circulating nucleic acid |
2 |
|
cisplatin - administration & dosage - adverse effects |
2 |
|
cisplatin - therapeutic use |
2 |
|
clinicopathologic features |
2 |
|
clonorchis sinensis |
2 |
|
colon cancer |
2 |
|
colonic neoplasms - complications - pathology |
2 |
|
common bile duct neoplasms - metabolism - pathology - virology |
2 |
|
computed tomography |
2 |
|
contrast media - administration & dosage |
2 |
|
copper/metabolism |
2 |
|
ctla-4 antigen |
2 |
|
cxcr3 ligands |
2 |
|
cyclin |
2 |
|
cyclin-dependent kinase |
2 |
|
cyclins - metabolism |
2 |
|
cyclooxygenase 2 - biosynthesis |
2 |
|
cyclooxygenase 2 inhibitors - therapeutic use |
2 |
|
cyclopamine |
2 |
|
cytoplasm |
2 |
|
database |
2 |
|
day surgery centre |
2 |
|
deamino arginine vasopressin - therapeutic use |
2 |
|
deficiency diseases - etiology |
2 |
|
dendritic cells |
2 |
|
dependovirus - genetics |
2 |
|
dna-binding proteins - deficiency - radiation effects |
2 |
|
donation of organs, tissues, etc. |
2 |
|
doppler ultrasound |
2 |
|
doxorubicin - administration & dosage - therapeutic use |
2 |
|
drainage - methods |
2 |
|
drug costs |
2 |
|
drug resistance, multiple |
2 |
|
drug resistance, neoplasm |
2 |
|
duodenal ulcer - complications |
2 |
|
electrobydraulic lithotripsy |
2 |
|
emulsions |
2 |
|
encapsulation |
2 |
|
endoglin |
2 |
|
endoscopes |
2 |
|
endoscopic sphincterotomy |
2 |
|
endoscopic sphincterotomy. |
2 |
|
endoscopy, digestive system |
2 |
|
endothelial cell |
2 |
|
endotoxin-neutralizing peptide |
2 |
|
energy metabolism - physiology |
2 |
|
enteral nutrition |
2 |
|
enzyme activation |
2 |
|
epidermal growth factor receptor inhibitors |
2 |
|
epoprostenol - administration & dosage |
2 |
|
epstein-barr virus |
2 |
|
erythrocytes - immunology |
2 |
|
esophageal and gastric varices - complications |
2 |
|
extended right lobe graft |
2 |
|
extrahepatic metastases |
2 |
|
extravasation of diagnostic and therapeutic materials - etiology - radiography |
2 |
|
familial amyloidotic polyneuropathy |
2 |
|
fat emulsions, intravenous - pharmacokinetics |
2 |
|
fatty acids, nonesterified - blood |
2 |
|
fetoprotein screening |
2 |
|
fever - etiology |
2 |
|
fever - physiopathology |
2 |
|
fibroblasts |
2 |
|
follicular dendritic cell tumour |
2 |
|
galactosamine - administration & dosage - economics |
2 |
|
galactosamine - adverse effects |
2 |
|
gallbladder - surgery |
2 |
|
gallbladder cancer |
2 |
|
gallbladder neoplasms - complications - surgery |
2 |
|
gallstones |
2 |
|
gallstones - radiography - therapy |
2 |
|
gallstones - surgery |
2 |
|
gallstones - therapy |
2 |
|
gallstones. |
2 |
|
gastrectomy |
2 |
|
gastric ulcer |
2 |
|
gastrointestinal haemorrhage |
2 |
|
gastrointestinal hemorrhage - complications - mortality - surgery - therapy |
2 |
|
gastroscopy |
2 |
|
gelatin sponge, absorbable - administration & dosage - adverse effects |
2 |
|
gene amplification |
2 |
|
general surgery - education |
2 |
|
genetic screening |
2 |
|
genetic vectors - standards |
2 |
|
glutamate-ammonia ligase - deficiency |
2 |
|
glycerol - blood |
2 |
|
gpi |
2 |
|
graft occlusion, vascular - prevention & control |
2 |
|
graft rejection - immunology - pathology |
2 |
|
graft survival - drug effects - immunology |
2 |
|
heart atria - surgery |
2 |
|
heart neoplasms - complications - diagnosis - surgery |
2 |
|
hedgehog |
2 |
|
hemoglobins - drug effects |
2 |
|
hemoglobinuria |
2 |
|
hemolysis |
2 |
|
hemorrhage - etiology |
2 |
|
hemorrhage - etiology - radiography - therapy |
2 |
|
hemostatics - therapeutic use |
2 |
|
hepatic arteries, chemotherapeutic infusion, 952.1266 |
2 |
|
hepatic arteries, therapeutic blockade, 952.1264 |
2 |
|
hepatic artery - radiography |
2 |
|
hepatic duct, common |
2 |
|
hepatic duct, common - radiography - surgery |
2 |
|
hepatic failure |
2 |
|
hepatic stellate cell |
2 |
|
hepatic vein |
2 |
|
hepatic venous outflow obstruction |
2 |
|
hepatitis b - surgery - therapy |
2 |
|
hepatitis c virus |
2 |
|
hepatocellular cacinoma |
2 |
|
hepatocellular carcinoma, subclinical |
2 |
|
hepatocyte |
2 |
|
hepatocyte growth factor |
2 |
|
hepatocyte nuclear factor 1α |
2 |
|
hepatolenticular degeneration |
2 |
|
hepatolenticular degeneration - blood - diagnosis - genetics |
2 |
|
hepatolithiasis. |
2 |
|
herpesvirus 4, human - isolation & purification |
2 |
|
historical perspective |
2 |
|
history, 20th century |
2 |
|
history, 21st century |
2 |
|
hong-kong chinese |
2 |
|
hsp90 heat-shock proteins - metabolism |
2 |
|
hydrogen-ion concentration |
2 |
|
hydroxybutyrates - blood |
2 |
|
hypothermia, induced |
2 |
|
hypoxia inducible factor-1α |
2 |
|
immunity, cellular |
2 |
|
immunohistochemistry - methods |
2 |
|
immunotherapy |
2 |
|
incomplete excision |
2 |
|
indocyanine green (icg) clearance |
2 |
|
indocyanine green clearance test |
2 |
|
infant, newborn |
2 |
|
inflammation - immunology - pathology |
2 |
|
insulinoma |
2 |
|
insulinoma - enzymology - pathology - secondary |
2 |
|
intercellular signaling peptides and proteins - biosynthesis - genetics - metabolism |
2 |
|
intercellular signaling peptides and proteins - genetics - metabolism |
2 |
|
international cooperation |
2 |
|
intestine, small - surgery |
2 |
|
intra-abdominal |
2 |
|
intrahepatic cholangiocarcinoma |
2 |
|
intrahepatic stones. |
2 |
|
intratumoral microvessel density |
2 |
|
iodized oil - administration & dosage - adverse effects |
2 |
|
iodized oil - administration and dosage |
2 |
|
isoantibodies - blood |
2 |
|
jejunostomy |
2 |
|
jurkat cells |
2 |
|
ki-67 antigen |
2 |
|
klatskin's tumor - radiography - surgery |
2 |
|
ku autoantigen |
2 |
|
leukocytes - immunology |
2 |
|
levovist® |
2 |
|
lipopolysaccharide |
2 |
|
lipopolysaccharides - metabolism |
2 |
|
lithotripsy - instrumentation - methods |
2 |
|
lithotripsy - methods |
2 |
|
liver - enzymology |
2 |
|
liver -- transplantation |
2 |
|
liver -- transplantation -- periodicals. |
2 |
|
liver -- transplantation. |
2 |
|
liver / transplantation |
2 |
|
liver cirrhosis - blood - complications - mortality |
2 |
|
liver cirrhosis - blood - surgery |
2 |
|
liver cirrhosis - complications - metabolism - virology |
2 |
|
liver cirrhosis - complications - pathology |
2 |
|
liver cirrhosis - metabolism - therapy |
2 |
|
liver diseases |
2 |
|
liver diseases - complications - physiopathology - surgery |
2 |
|
liver diseases - mortality - surgery |
2 |
|
liver failure - chemically induced - pathology - therapy |
2 |
|
liver failure, acute - chemically induced - metabolism - pathology |
2 |
|
liver function |
2 |
|
liver function reserve |
2 |
|
liver neoplasms - blood - complications - mortality - surgery |
2 |
|
liver neoplasms - blood supply - mortality - therapy |
2 |
|
liver neoplasms - complications - radiography |
2 |
|
liver neoplasms - complications - secondary |
2 |
|
liver neoplasms - complications - secondary - surgery |
2 |
|
liver neoplasms - diagnosis - epidemiology - surgery |
2 |
|
liver neoplasms - drug therapy - metabolism |
2 |
|
liver neoplasms - drug therapy - metabolism - mortality |
2 |
|
liver neoplasms - drug therapy - metabolism - pathology |
2 |
|
liver neoplasms - drug therapy - pathology |
2 |
|
liver neoplasms - genetics - immunology - pathology |
2 |
|
liver neoplasms - immunology - mortality - pathology |
2 |
|
liver neoplasms - metabolism - pathology - virology |
2 |
|
liver neoplasms - mortality - pathology |
2 |
|
liver neoplasms - mortality - pathology - surgery - virology |
2 |
|
liver neoplasms - pathology - radiography |
2 |
|
liver neoplasms - ultrasonography |
2 |
|
liver neoplasms, therapy, 761.321, 952.1266 |
2 |
|
liver transplantation - ethnology - immunology |
2 |
|
liver transplantation - history |
2 |
|
liver transplantation - history - methods |
2 |
|
living related donor transplantation |
2 |
|
living related donor transplantation -- periodicals. |
2 |
|
localization |
2 |
|
low-pressure pneumoperitoneum |
2 |
|
lymphocyte |
2 |
|
magnetic resonance imaging |
2 |
|
mdr1 |
2 |
|
mesenchymal stem cells |
2 |
|
met |
2 |
|
methods |
2 |
|
mib1 |
2 |
|
microarray |
2 |
|
microarrays |
2 |
|
middle hepatic vein |
2 |
|
models, molecular |
2 |
|
monoclonal antibody |
2 |
|
mouse |
2 |
|
mrp1 |
2 |
|
mt1-mmp/mmp14 |
2 |
|
multidrug resistance |
2 |
|
multiple drug resistance |
2 |
|
multiple endocrine neoplasia type 1 - enzymology |
2 |
|
multiple endocrine neoplasia type 2a |
2 |
|
multiple endocrine neoplasia type 2a - complications |
2 |
|
murine double minute 2 |
2 |
|
national protocol |
2 |
|
ndrg1 |
2 |
|
necrosis |
2 |
|
neoplasm proteins - analysis |
2 |
|
neoplasm recurrence, local - blood - epidemiology |
2 |
|
neoplasms, multiple primary |
2 |
|
neoplastic stem cells |
2 |
|
nf-κb |
2 |
|
nuclear proteins - analysis |
2 |
|
nuclear proteins - analysis - genetics |
2 |
|
nutritional status |
2 |
|
operative mortality |
2 |
|
organ allocation system |
2 |
|
organ donors |
2 |
|
organ donors. |
2 |
|
organ transplantation |
2 |
|
organs (anatomy) |
2 |
|
osmolar concentration |
2 |
|
outcome assessment (health care) |
2 |
|
p-glycoprotein - genetics - metabolism |
2 |
|
p-glycoprotein - metabolism |
2 |
|
pancreas - radiography |
2 |
|
pancreatic diseases - radiography |
2 |
|
pancreatic endocrine tumour |
2 |
|
pancreatic neoplasms - enzymology - pathology |
2 |
|
pancreatic pseudocyst - radiography |
2 |
|
pancreatitis |
2 |
|
pancreatitis - complications - etiology - mortality |
2 |
|
pancreatitis - etiology |
2 |
|
pancreatitis - etiology - mortality |
2 |
|
pancreatitis - etiology - therapy |
2 |
|
pancreatitis - radiography |
2 |
|
pancreatitis-diagnosis |
2 |
|
pancreatitis-drug-therapy |
2 |
|
pancreatitis. |
2 |
|
partial thromboplastin time |
2 |
|
pathologic features |
2 |
|
patient survival |
2 |
|
pc cell-derived growth factor |
2 |
|
pedigree |
2 |
|
peptic ulcer hemorrhage - diagnosis - mortality - pathology - therapy |
2 |
|
peptic ulcer hemorrhage - epidemiology - mortality - therapy |
2 |
|
peptic ulcer hemorrhage - mortality |
2 |
|
peptic ulcer. |
2 |
|
peptides - genetics - metabolism |
2 |
|
peritonitis - physiopathology |
2 |
|
pheochromocytoma |
2 |
|
pheochromocytoma - complications - diagnosis - surgery |
2 |
|
plasma exchange - methods |
2 |
|
plasma rna |
2 |
|
plasmapheresis |
2 |
|
plasmapheresis - methods |
2 |
|
polyneuropathies - genetics |
2 |
|
polysaccharides - administration & dosage |
2 |
|
portal vein embolization |
2 |
|
postoperative complications - etiology - mortality - surgery |
2 |
|
postoperative complications - mortality |
2 |
|
postoperative pain |
2 |
|
potassium - blood |
2 |
|
pregnancy |
2 |
|
pregnancy complications - surgery |
2 |
|
prognostication |
2 |
|
progranulin |
2 |
|
proliferating cell nuclear antigen - metabolism |
2 |
|
proliferation |
2 |
|
protein structure, secondary |
2 |
|
protein-energy malnutrition - etiology |
2 |
|
protein-serine-threonine kinases - deficiency - metabolism - radiation effects |
2 |
|
prothrombin time |
2 |
|
ptk787/zk22258 |
2 |
|
pulse |
2 |
|
purpura, thrombotic thrombocytopenic - blood - chemically induced |
2 |
|
radio-frequency ablation |
2 |
|
rat |
2 |
|
rats, inbred buf |
2 |
|
rats, inbred strains |
2 |
|
re-excision |
2 |
|
receptors, estrogen - analysis - biosynthesis |
2 |
|
recombination, genetic |
2 |
|
recurrent pyogenic cholangitis |
2 |
|
repeated resection |
2 |
|
right lobe graft |
2 |
|
rna, messenger - genetics |
2 |
|
scientific registry |
2 |
|
sensitivity |
2 |
|
sequence alignment |
2 |
|
seroepidemiologic studies |
2 |
|
serum albumin - metabolism |
2 |
|
serum alpha-fetoprotein |
2 |
|
severity-of-illness-index |
2 |
|
sex characteristics |
2 |
|
shock, septic - etiology |
2 |
|
shock, septic - physiopathology |
2 |
|
sodium - blood |
2 |
|
sodium salicylate - pharmacology |
2 |
|
somatostatin |
2 |
|
somatostatin-therapeutic-use |
2 |
|
specificity |
2 |
|
sphincterotomy, transhepatic - adverse effects |
2 |
|
split liver transplantation |
2 |
|
staining and labeling |
2 |
|
standard-pressure pneumoperitoneum |
2 |
|
stem cells |
2 |
|
stemcell |
2 |
|
stents - adverse effects |
2 |
|
stomach ulcer - complications - pathology |
2 |
|
sugar alcohol dehydrogenases - genetics |
2 |
|
suppuration |
2 |
|
surgical therapy |
2 |
|
surveillance network |
2 |
|
survival rates |
2 |
|
systemic therapy |
2 |
|
tacrolimus |
2 |
|
tacrolimus - administration & dosage - adverse effects |
2 |
|
telomerase |
2 |
|
telomerase - metabolism |
2 |
|
the asian pacific association for the study of the liver |
2 |
|
tnf-α |
2 |
|
transcription factors - genetics - metabolism |
2 |
|
transplantation of organs, tissues, etc. |
2 |
|
transthyretin gene |
2 |
|
treatment |
2 |
|
triglycerides - pharmacokinetics |
2 |
|
ttp |
2 |
|
tuberculosis - complications |
2 |
|
tumor differentiation |
2 |
|
tumor encapsulation |
2 |
|
tumor invasiveness |
2 |
|
tumor marker |
2 |
|
tumor markers |
2 |
|
tumor necrosis factor-alpha - metabolism |
2 |
|
tumor suppressor protein p53 - biosynthesis - genetics - metabolism |
2 |
|
tumor suppressor proteins - deficiency - radiation effects |
2 |
|
tyrosine kinase receptor b |
2 |
|
ubiquitin-protein ligases - metabolism |
2 |
|
ultrasonography |
2 |
|
ultrasonography, doppler, color |
2 |
|
ultrasound contrast agent |
2 |
|
valine - genetics |
2 |
|
vascular endothelial growth factor a - genetics - metabolism |
2 |
|
vascular invasion |
2 |
|
vena cava, inferior |
2 |
|
verapamil - administration & dosage - therapeutic use |
2 |
|
von hippel-lindau tumor suppressor protein |
2 |
|
women |
2 |
|
yc-1 |
2 |
|
α-fetoprotein |
2 |
|
abdomen |
1 |
|
abdomen, acute - diagnosis |
1 |
|
abdominal muscles |
1 |
|
abdominal wall. |
1 |
|
acetic acid - administration & dosage |
1 |
|
acetic acid injection |
1 |
|
actinomycosis |
1 |
|
actinomycosis - surgery |
1 |
|
acute appendicitis |
1 |
|
acute cholangitis |
1 |
|
adeno-associated viral vector |
1 |
|
adenosine triphosphate |
1 |
|
adhesives |
1 |
|
administration, topical |
1 |
|
afp |
1 |
|
albumin dialysis |
1 |
|
alcohol injection |
1 |
|
ampicillin - therapeutic use |
1 |
|
anastomosis |
1 |
|
anatomy |
1 |
|
anterior approach |
1 |
|
anti-bacterial agents - pharmacology - therapeutic use |
1 |
|
anti-bacterial agents - therapeutic use |
1 |
|
anti-infective agents |
1 |
|
antibodies - therapeutic use |
1 |
|
antibodies, bacterial - analysis |
1 |
|
appendectomy - economics |
1 |
|
appendicitis - complications - surgery |
1 |
|
appendicitis - diagnosis |
1 |
|
appendicitis - diagnosis - mortality - surgery |
1 |
|
appendicitis - drug therapy |
1 |
|
appendicitis - microbiology - pathology - surgery |
1 |
|
appendicitis - pathology - surgery |
1 |
|
appendix - pathology |
1 |
|
appendix - pathology - surgery |
1 |
|
arteriosclerosis |
1 |
|
autologous graft |
1 |
|
bacteria - drug effects - isolation & purification |
1 |
|
bacteria - isolation & purification |
1 |
|
bacteria, aerobic - isolation & purification |
1 |
|
bacteria, anaerobic - isolation & purification |
1 |
|
bacterial infections - complications |
1 |
|
bacterial infections - diagnosis - etiology |
1 |
|
bacterial infections - drug therapy - microbiology |
1 |
|
bacterial infections - prevention & control |
1 |
|
bacteriological techniques |
1 |
|
bacteroides fragilis |
1 |
|
bacteroides infections - prevention & control |
1 |
|
barium sulfate - diagnostic use |
1 |
|
bile duct diseases - radiography |
1 |
|
bile duct injury |
1 |
|
bile duct neoplasms - diagnosis - etiology - surgery |
1 |
|
bile duct stricture |
1 |
|
bile ducts - metabolism - physiopathology |
1 |
|
biliary |
1 |
|
biliary cystic disease |
1 |
|
biliary drainage |
1 |
|
biliary fistula - radiography |
1 |
|
biliary infection |
1 |
|
biliary tract diseases - surgery |
1 |
|
biliary tract surgical procedures |
1 |
|
bilirubin |
1 |
|
bleeding from ivc |
1 |
|
bleeding small intestinal lesions |
1 |
|
blood - microbiology |
1 |
|
body weights and measures |
1 |
|
branched-chain amino acid |
1 |
|
calcineurin - genetics - physiology |
1 |
|
carbon monoxide |
1 |
|
carcinoma - surgery |
1 |
|
carcinoma, hepatocellular - diagnosis - mortality - secondary - surgery |
1 |
|
caroli disease - complications - diagnosis |
1 |
|
caroli's disease |
1 |
|
catheterization - methods |
1 |
|
catheterization, central venous - adverse effects |
1 |
|
cecal diseases - etiology - surgery |
1 |
|
cefoperazone - therapeutic use |
1 |
|
cefotaxime - therapeutic use |
1 |
|
cefoxitin - therapeutic use |
1 |
|
central venous catheters |
1 |
|
charcot's triad |
1 |
|
children. |
1 |
|
cholangiocarcinoma - diagnosis - etiology - surgery |
1 |
|
cholangitis - complications |
1 |
|
cholangitis - diagnosis - physiopathology - surgery |
1 |
|
cholangitis - diagnosis - surgery |
1 |
|
cholecystec-tomy |
1 |
|
cholecystectomy |
1 |
|
cholecystostomy |
1 |
|
chronic rejection |
1 |
|
colitis - etiology - surgery |
1 |
|
colon - blood supply |
1 |
|
colon - surgery |
1 |
|
common bile duct - pathology - physiology - surgery |
1 |
|
common bile duct - physiopathology |
1 |
|
common bile duct diseases - radiography |
1 |
|
comorbidity |
1 |
|
costs and cost analysis |
1 |
|
cross infection - diagnosis |
1 |
|
cross infection - microbiology |
1 |
|
cryosurgery |
1 |
|
cysts - pathology - surgery |
1 |
|
diagnosis |
1 |
|
diagnostic criteria |
1 |
|
diagnostic imaging guidelines |
1 |
|
diatrizoate meglumine - adverse effects |
1 |
|
dissection - instrumentation |
1 |
|
donor safety |
1 |
|
donor selection |
1 |
|
drug administration schedule |
1 |
|
duodenal diseases - pathology - surgery |
1 |
|
duodenum - abnormalities - blood supply |
1 |
|
elastase |
1 |
|
elastin |
1 |
|
emergency |
1 |
|
endoscopic cholangiopancreatography |
1 |
|
endoscopy - methods |
1 |
|
endothelial cells |
1 |
|
energy metabolism |
1 |
|
epithelium - pathology |
1 |
|
equipment safety |
1 |
|
escherichia coli infections - prevention & control |
1 |
|
esophageal diseases - therapy |
1 |
|
esophageal fistula - etiology - therapy |
1 |
|
esophageal neoplasms - complications - surgery |
1 |
|
esophageal neoplasms - surgery |
1 |
|
esophagus - surgery |
1 |
|
evidence-based medicine |
1 |
|
false negative reactions |
1 |
|
fiber optic technology |
1 |
|
flexible choledochoscopy |
1 |
|
foreign bodies - therapy |
1 |
|
fosfomycin - pharmacology - therapeutic use |
1 |
|
fulminant hepatitis |
1 |
|
gallbladder diseases - diagnosis - pathology |
1 |
|
gallbladder diseases - radiography |
1 |
|
gallbladder drainage |
1 |
|
gallstones - pathology - therapy |
1 |
|
gangrene |
1 |
|
gastric cancer |
1 |
|
gastrointestinal bleeding |
1 |
|
gastrointestinal hemorrhage - diagnosis |
1 |
|
gastrointestinal hemorrhage - diagnosis - surgery |
1 |
|
gastrointestinal hemorrhage - etiology |
1 |
|
gastrointestinal hemorrhage - pathology |
1 |
|
gentamicin |
1 |
|
gentamicins - therapeutic use |
1 |
|
glass |
1 |
|
graft rejection - epidemiology - immunology |
1 |
|
graft rejection - immunology |
1 |
|
graft size |
1 |
|
grafting |
1 |
|
haemorrhage |
1 |
|
heart transplantation - immunology - pathology |
1 |
|
heme oxygenase |
1 |
|
hemofiltration |
1 |
|
hemostasis, surgical - instrumentation |
1 |
|
hepatic duct, common - radiography |
1 |
|
hepatic stellate cells - drug effects - metabolism |
1 |
|
hepatic veins - abnormalities - radiography |
1 |
|
hepatic veins - radiography - surgery |
1 |
|
hepaticocutaneous jejunostomy |
1 |
|
hepatitis b - pathology - prevention & control - surgery |
1 |
|
hepatoid |
1 |
|
hepatorenal syndrome |
1 |
|
homeostasis |
1 |
|
hsc |
1 |
|
ileal diseases - diagnosis - surgery |
1 |
|
immunoglobulin g - analysis |
1 |
|
infant care |
1 |
|
infarction - surgery |
1 |
|
infection |
1 |
|
inferior vena cava |
1 |
|
injections, intralesional |
1 |
|
intensive care, neonatal |
1 |
|
interferon-γ |
1 |
|
interleukin-10 |
1 |
|
intestinal diseases - pathology |
1 |
|
intestinal perforation - etiology - surgery |
1 |
|
intestinal perforation - microbiology - surgery |
1 |
|
intestinal perforation - pathology |
1 |
|
intestine, small - pathology |
1 |
|
intraoperative care |
1 |
|
intra‐operative enteroscopy |
1 |
|
intra‐operative fibreoptic enteroscopy |
1 |
|
ischemia - etiology |
1 |
|
ischemic colitis |
1 |
|
jejunal diseases - diagnosis - surgery |
1 |
|
jejunum - surgery |
1 |
|
jugular veins |
1 |
|
kawasaki disease |
1 |
|
key words: |
1 |
|
kinetics |
1 |
|
laparoscopic surgery |
1 |
|
leukocyte transfusion |
1 |
|
live-donor liver transplantation |
1 |
|
liver - anatomy & histology - surgery |
1 |
|
liver - physiology - radiography |
1 |
|
liver -- cancer -- adjuvant treatment -- congresses. |
1 |
|
liver -- cancer -- treatment -- congresses. |
1 |
|
liver -- cancer. |
1 |
|
liver cirrhosis - complications - mortality |
1 |
|
liver congestion |
1 |
|
liver failure - classification - diagnosis - physiopathology |
1 |
|
liver failure - etiology - prevention & control |
1 |
|
liver failure - mortality - therapy |
1 |
|
liver failure, acute - therapy |
1 |
|
liver neoplasms - diagnosis - mortality - pathology - surgery |
1 |
|
liver support |
1 |
|
liver support therapy |
1 |
|
liver transplantation (肝移植) |
1 |
|
liver transplantation - economics - methods |
1 |
|
liver transplantation - immunology - mortality |
1 |
|
liver transplantation - methods - trends |
1 |
|
liver, artificial - adverse effects |
1 |
|
living donor (活體肝移植) |
1 |
|
lymphadenitis - diagnosis |
1 |
|
lymphocyte transfusion |
1 |
|
major hepatectomy |
1 |
|
major histocompatibility complex class ii |
1 |
|
mars |
1 |
|
medium chain triglyceride |
1 |
|
metastasis. |
1 |
|
methicillin - pharmacology |
1 |
|
methylene blue - diagnostic use |
1 |
|
methylene blue injection |
1 |
|
metronidazole |
1 |
|
metronidazole - administration & dosage |
1 |
|
metronidazole - therapeutic use |
1 |
|
microbial sensitivity tests |
1 |
|
molecular adsorbent recirculation system |
1 |
|
monitoring, physiologic - methods |
1 |
|
moxalactam - therapeutic use |
1 |
|
mucocutaneous lymph node syndrome - complications |
1 |
|
multicenter studies as topic |
1 |
|
murphy's sign |
1 |
|
mycobacterium tuberculosis - isolation & purification |
1 |
|
necrosis - pathology |
1 |
|
netilmicin - administration & dosage |
1 |
|
netilmicin - administration & dosage - pharmacokinetics - therapeutic use |
1 |
|
normal stem cells |
1 |
|
oesophageal cancer |
1 |
|
open surgery |
1 |
|
operative outcome |
1 |
|
optimal irrigation pressures |
1 |
|
p38 mitogen-activated protein kinase |
1 |
|
pacific islands |
1 |
|
palpation |
1 |
|
pancreatic diseases - surgery |
1 |
|
pancreatic pleural effusion |
1 |
|
pancreaticopleural fistula |
1 |
|
pancreatitis - complications |
1 |
|
pancreatitis - diagnosis |
1 |
|
pancreatitis - mortality |
1 |
|
parenteral nutrition, total |
1 |
|
patient care planning |
1 |
|
pdgf |
1 |
|
peak expiratory flow rate |
1 |
|
penicillin resistance |
1 |
|
percutaneous |
1 |
|
perforated peptic ulcer |
1 |
|
peri-operative care |
1 |
|
phthalazines - pharmacology - therapeutic use |
1 |
|
platelet-derived growth factor - metabolism |
1 |
|
polyurethanes |
1 |
|
portal hypertension |
1 |
|
postappendicectomy sepsis |
1 |
|
postoperative complications - diagnosis |
1 |
|
postoperative liver failure |
1 |
|
povidone - analogs & derivatives |
1 |
|
povidone-iodine - therapeutic use |
1 |
|
practice guidelines |
1 |
|
premedication |
1 |
|
presentation |
1 |
|
pressure |
1 |
|
protein kinase inhibitors - pharmacology - therapeutic use |
1 |
|
pulmonary complications |
1 |
|
random allocation |
1 |
|
rats, inbred bn |
1 |
|
recipient prognosis |
1 |
|
reconstruction |
1 |
|
remodeling |
1 |
|
renal dialysis |
1 |
|
respiratory tract diseases - complications - diagnosis |
1 |
|
right lobe mobilization |
1 |
|
rigid choledochoscopy |
1 |
|
risk |
1 |
|
roux-en-y pancreatico-jejunostomy, distal pancreatectomy |
1 |
|
rupture |
1 |
|
schools, medical |
1 |
|
sepsis - drug therapy |
1 |
|
sepsis - etiology |
1 |
|
sepsis - etiology - microbiology |
1 |
|
sepsis - microbiology |
1 |
|
severity assessment |
1 |
|
sirolimus - therapeutic use |
1 |
|
skin - microbiology |
1 |
|
small intestinal lesions |
1 |
|
soluble guanylyl cyclase |
1 |
|
sphincterotomy |
1 |
|
sphincterotomy, transhepatic |
1 |
|
spleen - immunology |
1 |
|
sputum - microbiology |
1 |
|
staging |
1 |
|
staphylococcal infections - drug therapy |
1 |
|
staphylococcus aureus - drug effects |
1 |
|
stomach - surgery |
1 |
|
stomach diseases - therapy |
1 |
|
stomach neoplasms - complications - surgery |
1 |
|
stomach neoplasms - surgery |
1 |
|
suction |
1 |
|
surgical management |
1 |
|
surgical staplers |
1 |
|
surgical wound dehiscence - etiology - radiography |
1 |
|
surgical wound infection - drug therapy - prevention & control |
1 |
|
surgical wound infection - epidemiology |
1 |
|
surgical wound infection - etiology |
1 |
|
surgical wound infection - microbiology - prevention & control |
1 |
|
surgical wound infection - prevention & control |
1 |
|
surveillance hub cultures |
1 |
|
surveillance skin cultures |
1 |
|
technetium - diagnostic use |
1 |
|
tgf-β1 |
1 |
|
therapeutic irrigation |
1 |
|
topical povidone–iodine |
1 |
|
torsion abnormality |
1 |
|
transforming growth factor beta1 - metabolism |
1 |
|
transfusion |
1 |
|
transillumination |
1 |
|
transplant arteriosclerosis |
1 |
|
transplantation, homologous - immunology |
1 |
|
transplants |
1 |
|
tuberculin - immunology |
1 |
|
tuberculosis - diagnosis - epidemiology |
1 |
|
tuberculosis, pulmonary - diagnosis |
1 |
|
tuberculosis, renal - diagnosis |
1 |
|
tuberculosis, urogenital - diagnosis |
1 |
|
ultrasonic dissector |
1 |
|
ultrasonics |
1 |
|
universities |
1 |
|
vena cava, inferior - radiography - surgery |
1 |
